A Trial To Assess The Safety, Tolerability, And Immunogenicity Of Rlp2086 Vaccine When Administered In Either 2- Or 3-Dose Regimens In Healthy Subjects Aged ≥11 To <19 Years

A Phase 2, Randomized, Placebo-controlled, Single-blind Trial To Assess The Safety, Tolerability, And Immunogenicity Of Bivalent Rlp2086 Vaccine When Administered In Either 2- Or 3-dose Regimens In Healthy Subjects Aged Greater Than Or Equal To 11 To <19 Years

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01299480

Enrollment

1714

Registered

2011-02-18

Start date

2011-03-03

Completion date

2012-09-18

Last updated

2022-10-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Meningococcal Vaccine

Keywords

Healthy adolescents

Brief summary

This study is to look at a new vaccine that might prevent meningococcal disease, and to look at the safety of the new vaccine as well as how well it is tolerated. This study will also look at this vaccine being given 2 or 3 times. This study will be done in healthy adolescents.

Interventions

BIOLOGICALVaccine

rLP2086 vaccine at visits 1, 2 and 5, saline at visit 3

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

PREVENTION

Masking

SINGLE (Subject)

Eligibility

Sex/Gender

ALL

Age

11 Years to 18 Years

Healthy volunteers

Yes

Inclusion criteria

* Evidence of a personally signed and dated informed consent document indicating that the parent/legally acceptable representative and/or subject has been informed of all pertinent aspects of the study. * Parent/legally acceptable representative and/or subjects who are willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures. * Male or female subject aged ≥11 and \<19 years at the time of enrollment. * Available for the entire study period and can be reached by telephone. * Healthy subject as determined by medical history, physical examination, and judgment of the investigator. * All male and female subjects must agree to practice a form of effective contraception, such as barrier contraception (ie, condom plus spermicide, a female condom, diaphragm, cervical cap or intrauterine device), implants, injectables, combined oral contraceptives or sexual abstinence prior to entering into the study, for the duration of the vaccination period and for 28 days after the last study vaccination.For Germany: The phrase sexual abstinence is not applicable, with the understanding that all male and all female subjects of childbearing potential must practice an effective form of contraception during the study. * Negative urine pregnancy test for female subjects.

Exclusion criteria

* Previous vaccination with any meningococcal serogroup B vaccine. * A previous anaphylactic reaction to any vaccine or vaccine-related component. * Bleeding diathesis or condition associated with prolonged bleeding time that would contraindicate intramuscular injection. * A known or suspected disease of the immune system or those receiving immunosuppressive therapy. * History of culture-proven disease caused by Neisseria meningitidis or Neisseria gonorrhoeae. * Significant neurological disorder or history of seizure (excluding simple febrile seizure). * Receipt of any blood products, including immunoglobulin within 6 months before the first study vaccination. * Current chronic use of systemic antibiotics. * Participation in other studies during study participation. Participation in purely observational studies is acceptable. * Received any investigational drugs, vaccines or devices within 28 days before administration of the first study vaccination. * Any neuroinflammatory or autoimmune condition, including, but not limited to, transverse myelitis, uveitis, optic neuritis, and multiple sclerosis. * Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the subject inappropriate for entry into this study. * Subjects who are investigational site staff members or subjects who are Pfizer employees directly involved in the conduct of the trial. * Subject is pregnant or breastfeeding. * Subject is a direct descendant of study site or Pfizer personnel

Design outcomes

Primary

Measure	Time frame
Percentage of Participants Reporting At Least 1 Adverse Event (AE)	Injection 1 up to 1 month after Injection 4
Percentage of Participants Achieving Serum Bactericidal Assay Using Human Complement (hSBA) Titer Greater Than or Equal to (>=) Lower Limit of Quantitation: Group 1 and 2 Participants	1 month after Injection 4

Secondary

Measure	Time frame
Serum Bactericidal Assay Using Human Complement (hSBA) Geometric Mean Titers (GMTs)	Before Injection (Inj) 1, 1 Month (M) after (aft) Injection 2, 3, 4
Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	Before Injection 1, 1 Month after Injection 2, 3, 4
Percentage of Participants Achieving hSBA Titer >=LLOQ	Before Injection 1, 1 Month after Injection 2, 3, 4
Percentage of Participants Achieving hSBA Titer >=LLOQ: Group 3 Participants	1 month after Injection 4

Other

Measure	Time frame
Percentage of Participants Achieving At Least 4-fold Increase in hSBA Titer	1 month after Injection 2, 3, 4

Countries

Czechia, Denmark, Finland, Germany, Poland, Spain, Sweden

Participant flow

Pre-assignment details

A total of 1714 participants were enrolled in this study. Of these, 1 participant was not randomized but was vaccinated with Saline at Injection 1. This participant was included in safety population and not intent-to-treat population. Participant Flow includes only randomized intent to treat participants.

Participants by arm

Arm	Count
Group 1:rLP2086(0-,1-,6- Month)+Saline(2- Month) Randomized to receive rLP2086 on a 0-, 1-, 6- month and 0.9% normal saline on a 2- month schedule.	427
Group 2:rLP2086(0-,2-,6- Month)+Saline(1- Month) Randomized to receive rLP2086 on a 0-, 2-, 6- month and 0.9% normal saline on a 1- month schedule.	430
Group 3: rLP2086(0-,6- Month)+Saline(1-,2- Month) Randomized to receive rLP2086 on a 0-, 6- month and 0.9% normal saline on a 1-, 2- month schedule.	427
Group 4: rLP2086(0-,2- Month)+Saline(1-,6- Month) Randomized to receive rLP2086 on a 0-, 2- month and 0.9% normal saline on a 1-, 6- month schedule.	286
Group 5: rLP2086(2-,6- Month)+ Saline(0-,1- Month) Randomized to receive rLP2086 on a 2-, 6- month and 0.9% normal saline on a 0-, 1- month schedule.	143
Total	1,713

Withdrawals & dropouts

Period	Reason	FG000	FG001	FG002	FG003	FG004
Overall Study	Adverse Event	6	4	5	4	0
Overall Study	Lost to Follow-up	3	1	2	1	2
Overall Study	No longer willing to participate	19	17	14	13	10
Overall Study	Other	3	2	3	0	3
Overall Study	Physician Decision	1	1	0	2	0
Overall Study	Protocol Violation	7	5	8	1	1
Overall Study	Started, but not vaccinated	0	0	1	1	0
Overall Study	Withdrawal by Subject	3	4	7	3	4
Overall Study	Withdrawal due to pregnancy	0	1	1	0	0

Baseline characteristics

Characteristic	Group 1:rLP2086(0-,1-,6- Month)+Saline(2- Month)	Group 2:rLP2086(0-,2-,6- Month)+Saline(1- Month)	Group 3: rLP2086(0-,6- Month)+Saline(1-,2- Month)	Group 4: rLP2086(0-,2- Month)+Saline(1-,6- Month)	Group 5: rLP2086(2-,6- Month)+ Saline(0-,1- Month)	Total
Age, Customized 11- less than (<) 14 years	156 participants	158 participants	156 participants	106 participants	53 participants	629 participants
Age, Customized 14 - <19 years	271 participants	272 participants	271 participants	180 participants	90 participants	1084 participants
Sex: Female, Male Female	212 Participants	225 Participants	216 Participants	139 Participants	79 Participants	871 Participants
Sex: Female, Male Male	215 Participants	205 Participants	211 Participants	147 Participants	64 Participants	842 Participants

Adverse events

Event type	EG000 affected / at risk	EG001 affected / at risk	EG002 affected / at risk	EG003 affected / at risk	EG004 affected / at risk
deaths Total, all-cause mortality	— / —	— / —	— / —	— / —	— / —
other Total, other adverse events	113 / 426	115 / 414	114 / 451	72 / 277	43 / 144
serious Total, serious adverse events	12 / 426	14 / 414	7 / 451	7 / 277	3 / 144

Outcome results

Primary

Percentage of Participants Achieving Serum Bactericidal Assay Using Human Complement (hSBA) Titer Greater Than or Equal to (>=) Lower Limit of Quantitation: Group 1 and 2 Participants

Time frame: 1 month after Injection 4

Population: The number of participants shown for each test strain represents the number with valid and determinant assay result for that strain.

Arm	Measure	Group	Value (NUMBER)
Group 1:rLP2086(0-,1-,6- Month)+Saline(2- Month)	Percentage of Participants Achieving Serum Bactericidal Assay Using Human Complement (hSBA) Titer Greater Than or Equal to (>=) Lower Limit of Quantitation: Group 1 and 2 Participants	PMB80 [A22] 1:8 (N=360, 357)	91.7 percentage of participants
Group 1:rLP2086(0-,1-,6- Month)+Saline(2- Month)	Percentage of Participants Achieving Serum Bactericidal Assay Using Human Complement (hSBA) Titer Greater Than or Equal to (>=) Lower Limit of Quantitation: Group 1 and 2 Participants	PMB2001 [A56] 1:8 (N=362, 359)	99.4 percentage of participants
Group 1:rLP2086(0-,1-,6- Month)+Saline(2- Month)	Percentage of Participants Achieving Serum Bactericidal Assay Using Human Complement (hSBA) Titer Greater Than or Equal to (>=) Lower Limit of Quantitation: Group 1 and 2 Participants	PMB2948 [B24] 1:8 (N=354, 354)	89.0 percentage of participants
Group 1:rLP2086(0-,1-,6- Month)+Saline(2- Month)	Percentage of Participants Achieving Serum Bactericidal Assay Using Human Complement (hSBA) Titer Greater Than or Equal to (>=) Lower Limit of Quantitation: Group 1 and 2 Participants	PMB2707 [B44] 1:8 (N356, 352)	88.5 percentage of participants
Group 2:rLP2086(0-,2-,6- Month)+Saline(1- Month)	Percentage of Participants Achieving Serum Bactericidal Assay Using Human Complement (hSBA) Titer Greater Than or Equal to (>=) Lower Limit of Quantitation: Group 1 and 2 Participants	PMB2707 [B44] 1:8 (N356, 352)	86.1 percentage of participants
Group 2:rLP2086(0-,2-,6- Month)+Saline(1- Month)	Percentage of Participants Achieving Serum Bactericidal Assay Using Human Complement (hSBA) Titer Greater Than or Equal to (>=) Lower Limit of Quantitation: Group 1 and 2 Participants	PMB80 [A22] 1:8 (N=360, 357)	95.0 percentage of participants
Group 2:rLP2086(0-,2-,6- Month)+Saline(1- Month)	Percentage of Participants Achieving Serum Bactericidal Assay Using Human Complement (hSBA) Titer Greater Than or Equal to (>=) Lower Limit of Quantitation: Group 1 and 2 Participants	PMB2948 [B24] 1:8 (N=354, 354)	88.4 percentage of participants
Group 2:rLP2086(0-,2-,6- Month)+Saline(1- Month)	Percentage of Participants Achieving Serum Bactericidal Assay Using Human Complement (hSBA) Titer Greater Than or Equal to (>=) Lower Limit of Quantitation: Group 1 and 2 Participants	PMB2001 [A56] 1:8 (N=362, 359)	98.9 percentage of participants

Comparison: PMB80 \[A22\]: Response rate was compared with 50%, using 1-sided exact test based on binomial distribution. p-Value \<0.0125 was considered significant.p-value: <0.001Binomial Distribution

Comparison: PMB2001 \[A56\]: Response rate was compared with 50%, using 1-sided exact test based on binomial distribution. p-Value \<0.0125 was considered significant.p-value: <0.001Binomial Distribution

Comparison: PMB2948 \[B24\]: Response rate was compared with 50%, using 1-sided exact test based on binomial distribution. p-Value \<0.0125 was considered significant.p-value: <0.001Binomial Distribution

Comparison: PMB2707 \[B44\]: Response rate was compared with 50%, using 1-sided exact test based on binomial distribution. p-Value \<0.0125 was considered significant.p-value: <0.001Binomial Distribution

Primary

Percentage of Participants Reporting At Least 1 Adverse Event (AE)

Time frame: Injection 1 up to 1 month after Injection 4

Population: Some participants randomized to receive vaccination as per Groups 1, 2 or 4 schedules actually received vaccination as per Group 3 schedule. One participant was not randomized but received Saline at Injection 1 and was included in Group 5. Participants have been presented as per actual administration schedule received.

Arm	Measure	Value (NUMBER)
Group 1:rLP2086(0-,1-,6- Month)+Saline(2- Month)	Percentage of Participants Reporting At Least 1 Adverse Event (AE)	36.9 percentage of participants
Group 2:rLP2086(0-,2-,6- Month)+Saline(1- Month)	Percentage of Participants Reporting At Least 1 Adverse Event (AE)	35.7 percentage of participants
Group 3: rLP2086(0-,6- Month)+Saline(1-,2- Month)	Percentage of Participants Reporting At Least 1 Adverse Event (AE)	35.5 percentage of participants
Group 4: rLP2086(0-,2- Month)+Saline(1-,6- Month)	Percentage of Participants Reporting At Least 1 Adverse Event (AE)	35.7 percentage of participants
Group 5: rLP2086(2-,6- Month)+ Saline(0-,1- Month)	Percentage of Participants Reporting At Least 1 Adverse Event (AE)	37.5 percentage of participants

Secondary

Percentage of Participants Achieving hSBA Titer >=LLOQ

Time frame: Before Injection 1, 1 Month after Injection 2, 3, 4

Population: The number of participants shown for each test strain represents the number with valid and determinant assay result for that strain.

Arm	Measure	Group	Value (NUMBER)
Group 1:rLP2086(0-,1-,6- Month)+Saline(2- Month)	Percentage of Participants Achieving hSBA Titer >=LLOQ	Before Inj1: PMB80[A22] 1:8; N=356,352,364,235,108	28.1 percentage of participants
Group 1:rLP2086(0-,1-,6- Month)+Saline(2- Month)	Percentage of Participants Achieving hSBA Titer >=LLOQ	1M aft Inj4:PMB2001[A56]1:8; N=362,359,370,228,113	99.4 percentage of participants
Group 1:rLP2086(0-,1-,6- Month)+Saline(2- Month)	Percentage of Participants Achieving hSBA Titer >=LLOQ	1M aft Inj3:PMB2948[B24]1:8; N=328,337,340,237,102	50.6 percentage of participants
Group 1:rLP2086(0-,1-,6- Month)+Saline(2- Month)	Percentage of Participants Achieving hSBA Titer >=LLOQ	1M aft Inj3;PMB2001[A56]1:8; N=329,339,320,240,102	89.1 percentage of participants
Group 1:rLP2086(0-,1-,6- Month)+Saline(2- Month)	Percentage of Participants Achieving hSBA Titer >=LLOQ	Before Inj1:PMB2001[A56]1:8; N=350,348,355,231,107	20.9 percentage of participants
Group 1:rLP2086(0-,1-,6- Month)+Saline(2- Month)	Percentage of Participants Achieving hSBA Titer >=LLOQ	1M aft Inj4:PMB2948[B24]1:8; N=354,354,359,228,110	89.0 percentage of participants
Group 1:rLP2086(0-,1-,6- Month)+Saline(2- Month)	Percentage of Participants Achieving hSBA Titer >=LLOQ	1M aft Inj3:PMB2707[B44]1:8; N=333,331,341,234,105	35.4 percentage of participants
Group 1:rLP2086(0-,1-,6- Month)+Saline(2- Month)	Percentage of Participants Achieving hSBA Titer >=LLOQ	1M aft Inj2:PMB2001[A56]1:8; N=353,329,335,218,102	96.6 percentage of participants
Group 1:rLP2086(0-,1-,6- Month)+Saline(2- Month)	Percentage of Participants Achieving hSBA Titer >=LLOQ	1M aft Inj2:PMB2948[B24]1:8; N=344,345,352,223,110	62.2 percentage of participants
Group 1:rLP2086(0-,1-,6- Month)+Saline(2- Month)	Percentage of Participants Achieving hSBA Titer >=LLOQ	Before Inj1:PMB2948[B24]1:8; N=362,356,369,241,112	16.3 percentage of participants
Group 1:rLP2086(0-,1-,6- Month)+Saline(2- Month)	Percentage of Participants Achieving hSBA Titer >=LLOQ	1M aft Inj4:PMB2707[B44]1:8; N=356,352,356,230,111	88.5 percentage of participants
Group 1:rLP2086(0-,1-,6- Month)+Saline(2- Month)	Percentage of Participants Achieving hSBA Titer >=LLOQ	Before Inj1:PMB2707[B44]1:8; N=363,357,370,241,113	5.2 percentage of participants
Group 1:rLP2086(0-,1-,6- Month)+Saline(2- Month)	Percentage of Participants Achieving hSBA Titer >=LLOQ	1M aft Inj3:PMB80[A22]1:8; N=332,344,340,238,102	63.0 percentage of participants
Group 1:rLP2086(0-,1-,6- Month)+Saline(2- Month)	Percentage of Participants Achieving hSBA Titer >=LLOQ	1M aft Inj2:PMB2707[B44]1:8; N=341,345,349,225,111	54.0 percentage of participants
Group 1:rLP2086(0-,1-,6- Month)+Saline(2- Month)	Percentage of Participants Achieving hSBA Titer >=LLOQ	1M aft Inj2:PMB80[A22]1:8; N=351,345,351,224,110	74.6 percentage of participants
Group 1:rLP2086(0-,1-,6- Month)+Saline(2- Month)	Percentage of Participants Achieving hSBA Titer >=LLOQ	1M aft Inj4:PMB80[A22]1:8; N=360,357,369,234,111	91.7 percentage of participants
Group 2:rLP2086(0-,2-,6- Month)+Saline(1- Month)	Percentage of Participants Achieving hSBA Titer >=LLOQ	Before Inj1:PMB2948[B24]1:8; N=362,356,369,241,112	13.8 percentage of participants
Group 2:rLP2086(0-,2-,6- Month)+Saline(1- Month)	Percentage of Participants Achieving hSBA Titer >=LLOQ	1M aft Inj3:PMB2948[B24]1:8; N=328,337,340,237,102	70.3 percentage of participants
Group 2:rLP2086(0-,2-,6- Month)+Saline(1- Month)	Percentage of Participants Achieving hSBA Titer >=LLOQ	Before Inj1:PMB2707[B44]1:8; N=363,357,370,241,113	6.2 percentage of participants
Group 2:rLP2086(0-,2-,6- Month)+Saline(1- Month)	Percentage of Participants Achieving hSBA Titer >=LLOQ	1M aft Inj4:PMB2948[B24]1:8; N=354,354,359,228,110	88.4 percentage of participants
Group 2:rLP2086(0-,2-,6- Month)+Saline(1- Month)	Percentage of Participants Achieving hSBA Titer >=LLOQ	1M aft Inj3:PMB80[A22]1:8; N=332,344,340,238,102	88.7 percentage of participants
Group 2:rLP2086(0-,2-,6- Month)+Saline(1- Month)	Percentage of Participants Achieving hSBA Titer >=LLOQ	1M aft Inj4:PMB80[A22]1:8; N=360,357,369,234,111	95.0 percentage of participants
Group 2:rLP2086(0-,2-,6- Month)+Saline(1- Month)	Percentage of Participants Achieving hSBA Titer >=LLOQ	Before Inj1: PMB80[A22] 1:8; N=356,352,364,235,108	21.9 percentage of participants
Group 2:rLP2086(0-,2-,6- Month)+Saline(1- Month)	Percentage of Participants Achieving hSBA Titer >=LLOQ	Before Inj1:PMB2001[A56]1:8; N=350,348,355,231,107	18.7 percentage of participants
Group 2:rLP2086(0-,2-,6- Month)+Saline(1- Month)	Percentage of Participants Achieving hSBA Titer >=LLOQ	1M aft Inj3:PMB2707[B44]1:8; N=333,331,341,234,105	61.9 percentage of participants
Group 2:rLP2086(0-,2-,6- Month)+Saline(1- Month)	Percentage of Participants Achieving hSBA Titer >=LLOQ	1M aft Inj2:PMB2001[A56]1:8; N=353,329,335,218,102	56.2 percentage of participants
Group 2:rLP2086(0-,2-,6- Month)+Saline(1- Month)	Percentage of Participants Achieving hSBA Titer >=LLOQ	1M aft Inj3;PMB2001[A56]1:8; N=329,339,320,240,102	97.9 percentage of participants
Group 2:rLP2086(0-,2-,6- Month)+Saline(1- Month)	Percentage of Participants Achieving hSBA Titer >=LLOQ	1M aft Inj4:PMB2707[B44]1:8; N=356,352,356,230,111	86.1 percentage of participants
Group 2:rLP2086(0-,2-,6- Month)+Saline(1- Month)	Percentage of Participants Achieving hSBA Titer >=LLOQ	1M aft Inj4:PMB2001[A56]1:8; N=362,359,370,228,113	98.9 percentage of participants
Group 2:rLP2086(0-,2-,6- Month)+Saline(1- Month)	Percentage of Participants Achieving hSBA Titer >=LLOQ	1M aft Inj2:PMB2707[B44]1:8; N=341,345,349,225,111	15.7 percentage of participants
Group 2:rLP2086(0-,2-,6- Month)+Saline(1- Month)	Percentage of Participants Achieving hSBA Titer >=LLOQ	1M aft Inj2:PMB80[A22]1:8; N=351,345,351,224,110	46.7 percentage of participants
Group 2:rLP2086(0-,2-,6- Month)+Saline(1- Month)	Percentage of Participants Achieving hSBA Titer >=LLOQ	1M aft Inj2:PMB2948[B24]1:8; N=344,345,352,223,110	39.4 percentage of participants
Group 3: rLP2086(0-,6- Month)+Saline(1-,2- Month)	Percentage of Participants Achieving hSBA Titer >=LLOQ	1M aft Inj3;PMB2001[A56]1:8; N=329,339,320,240,102	50.6 percentage of participants
Group 3: rLP2086(0-,6- Month)+Saline(1-,2- Month)	Percentage of Participants Achieving hSBA Titer >=LLOQ	1M aft Inj2:PMB2948[B24]1:8; N=344,345,352,223,110	43.8 percentage of participants
Group 3: rLP2086(0-,6- Month)+Saline(1-,2- Month)	Percentage of Participants Achieving hSBA Titer >=LLOQ	1M aft Inj2:PMB2707[B44]1:8; N=341,345,349,225,111	17.8 percentage of participants
Group 3: rLP2086(0-,6- Month)+Saline(1-,2- Month)	Percentage of Participants Achieving hSBA Titer >=LLOQ	1M aft Inj4:PMB80[A22]1:8; N=360,357,369,234,111	93.5 percentage of participants
Group 3: rLP2086(0-,6- Month)+Saline(1-,2- Month)	Percentage of Participants Achieving hSBA Titer >=LLOQ	1M aft Inj3:PMB2948[B24]1:8; N=328,337,340,237,102	35.6 percentage of participants
Group 3: rLP2086(0-,6- Month)+Saline(1-,2- Month)	Percentage of Participants Achieving hSBA Titer >=LLOQ	1M aft Inj4:PMB2001[A56]1:8; N=362,359,370,228,113	98.4 percentage of participants
Group 3: rLP2086(0-,6- Month)+Saline(1-,2- Month)	Percentage of Participants Achieving hSBA Titer >=LLOQ	1M aft Inj3:PMB80[A22]1:8; N=332,344,340,238,102	44.7 percentage of participants
Group 3: rLP2086(0-,6- Month)+Saline(1-,2- Month)	Percentage of Participants Achieving hSBA Titer >=LLOQ	Before Inj1:PMB2707[B44]1:8; N=363,357,370,241,113	6.2 percentage of participants
Group 3: rLP2086(0-,6- Month)+Saline(1-,2- Month)	Percentage of Participants Achieving hSBA Titer >=LLOQ	1M aft Inj4:PMB2948[B24]1:8; N=354,354,359,228,110	81.1 percentage of participants
Group 3: rLP2086(0-,6- Month)+Saline(1-,2- Month)	Percentage of Participants Achieving hSBA Titer >=LLOQ	Before Inj1: PMB80[A22] 1:8; N=356,352,364,235,108	24.7 percentage of participants
Group 3: rLP2086(0-,6- Month)+Saline(1-,2- Month)	Percentage of Participants Achieving hSBA Titer >=LLOQ	1M aft Inj2:PMB80[A22]1:8; N=351,345,351,224,110	51.3 percentage of participants
Group 3: rLP2086(0-,6- Month)+Saline(1-,2- Month)	Percentage of Participants Achieving hSBA Titer >=LLOQ	1M aft Inj2:PMB2001[A56]1:8; N=353,329,335,218,102	58.8 percentage of participants
Group 3: rLP2086(0-,6- Month)+Saline(1-,2- Month)	Percentage of Participants Achieving hSBA Titer >=LLOQ	1M aft Inj4:PMB2707[B44]1:8; N=356,352,356,230,111	77.5 percentage of participants
Group 3: rLP2086(0-,6- Month)+Saline(1-,2- Month)	Percentage of Participants Achieving hSBA Titer >=LLOQ	Before Inj1:PMB2001[A56]1:8; N=350,348,355,231,107	21.7 percentage of participants
Group 3: rLP2086(0-,6- Month)+Saline(1-,2- Month)	Percentage of Participants Achieving hSBA Titer >=LLOQ	1M aft Inj3:PMB2707[B44]1:8; N=333,331,341,234,105	12.6 percentage of participants
Group 3: rLP2086(0-,6- Month)+Saline(1-,2- Month)	Percentage of Participants Achieving hSBA Titer >=LLOQ	Before Inj1:PMB2948[B24]1:8; N=362,356,369,241,112	13.0 percentage of participants
Group 4: rLP2086(0-,2- Month)+Saline(1-,6- Month)	Percentage of Participants Achieving hSBA Titer >=LLOQ	1M aft Inj2:PMB80[A22]1:8; N=351,345,351,224,110	52.2 percentage of participants
Group 4: rLP2086(0-,2- Month)+Saline(1-,6- Month)	Percentage of Participants Achieving hSBA Titer >=LLOQ	Before Inj1: PMB80[A22] 1:8; N=356,352,364,235,108	22.6 percentage of participants
Group 4: rLP2086(0-,2- Month)+Saline(1-,6- Month)	Percentage of Participants Achieving hSBA Titer >=LLOQ	1M aft Inj3:PMB80[A22]1:8; N=332,344,340,238,102	90.8 percentage of participants
Group 4: rLP2086(0-,2- Month)+Saline(1-,6- Month)	Percentage of Participants Achieving hSBA Titer >=LLOQ	1M aft Inj4:PMB80[A22]1:8; N=360,357,369,234,111	57.7 percentage of participants
Group 4: rLP2086(0-,2- Month)+Saline(1-,6- Month)	Percentage of Participants Achieving hSBA Titer >=LLOQ	Before Inj1:PMB2001[A56]1:8; N=350,348,355,231,107	19.0 percentage of participants
Group 4: rLP2086(0-,2- Month)+Saline(1-,6- Month)	Percentage of Participants Achieving hSBA Titer >=LLOQ	1M aft Inj2:PMB2001[A56]1:8; N=353,329,335,218,102	56.0 percentage of participants
Group 4: rLP2086(0-,2- Month)+Saline(1-,6- Month)	Percentage of Participants Achieving hSBA Titer >=LLOQ	1M aft Inj3;PMB2001[A56]1:8; N=329,339,320,240,102	100.0 percentage of participants
Group 4: rLP2086(0-,2- Month)+Saline(1-,6- Month)	Percentage of Participants Achieving hSBA Titer >=LLOQ	1M aft Inj4:PMB2001[A56]1:8; N=362,359,370,228,113	76.8 percentage of participants
Group 4: rLP2086(0-,2- Month)+Saline(1-,6- Month)	Percentage of Participants Achieving hSBA Titer >=LLOQ	Before Inj1:PMB2948[B24]1:8; N=362,356,369,241,112	11.2 percentage of participants
Group 4: rLP2086(0-,2- Month)+Saline(1-,6- Month)	Percentage of Participants Achieving hSBA Titer >=LLOQ	1M aft Inj2:PMB2948[B24]1:8; N=344,345,352,223,110	45.3 percentage of participants
Group 4: rLP2086(0-,2- Month)+Saline(1-,6- Month)	Percentage of Participants Achieving hSBA Titer >=LLOQ	1M aft Inj3:PMB2948[B24]1:8; N=328,337,340,237,102	73.0 percentage of participants
Group 4: rLP2086(0-,2- Month)+Saline(1-,6- Month)	Percentage of Participants Achieving hSBA Titer >=LLOQ	1M aft Inj4:PMB2948[B24]1:8; N=354,354,359,228,110	35.5 percentage of participants
Group 4: rLP2086(0-,2- Month)+Saline(1-,6- Month)	Percentage of Participants Achieving hSBA Titer >=LLOQ	Before Inj1:PMB2707[B44]1:8; N=363,357,370,241,113	7.5 percentage of participants
Group 4: rLP2086(0-,2- Month)+Saline(1-,6- Month)	Percentage of Participants Achieving hSBA Titer >=LLOQ	1M aft Inj2:PMB2707[B44]1:8; N=341,345,349,225,111	18.2 percentage of participants
Group 4: rLP2086(0-,2- Month)+Saline(1-,6- Month)	Percentage of Participants Achieving hSBA Titer >=LLOQ	1M aft Inj3:PMB2707[B44]1:8; N=333,331,341,234,105	70.1 percentage of participants
Group 4: rLP2086(0-,2- Month)+Saline(1-,6- Month)	Percentage of Participants Achieving hSBA Titer >=LLOQ	1M aft Inj4:PMB2707[B44]1:8; N=356,352,356,230,111	23.9 percentage of participants
Group 5: rLP2086(2-,6- Month)+ Saline(0-,1- Month)	Percentage of Participants Achieving hSBA Titer >=LLOQ	Before Inj1:PMB2707[B44]1:8; N=363,357,370,241,113	4.4 percentage of participants
Group 5: rLP2086(2-,6- Month)+ Saline(0-,1- Month)	Percentage of Participants Achieving hSBA Titer >=LLOQ	Before Inj1:PMB2948[B24]1:8; N=362,356,369,241,112	14.3 percentage of participants
Group 5: rLP2086(2-,6- Month)+ Saline(0-,1- Month)	Percentage of Participants Achieving hSBA Titer >=LLOQ	1M aft Inj4:PMB2001[A56]1:8; N=362,359,370,228,113	99.1 percentage of participants
Group 5: rLP2086(2-,6- Month)+ Saline(0-,1- Month)	Percentage of Participants Achieving hSBA Titer >=LLOQ	1M aft Inj3;PMB2001[A56]1:8; N=329,339,320,240,102	67.6 percentage of participants
Group 5: rLP2086(2-,6- Month)+ Saline(0-,1- Month)	Percentage of Participants Achieving hSBA Titer >=LLOQ	1M aft Inj3:PMB80[A22]1:8; N=332,344,340,238,102	55.9 percentage of participants
Group 5: rLP2086(2-,6- Month)+ Saline(0-,1- Month)	Percentage of Participants Achieving hSBA Titer >=LLOQ	1M aft Inj2:PMB2707[B44]1:8; N=341,345,349,225,111	4.5 percentage of participants
Group 5: rLP2086(2-,6- Month)+ Saline(0-,1- Month)	Percentage of Participants Achieving hSBA Titer >=LLOQ	1M aft Inj2:PMB2001[A56]1:8; N=353,329,335,218,102	22.5 percentage of participants
Group 5: rLP2086(2-,6- Month)+ Saline(0-,1- Month)	Percentage of Participants Achieving hSBA Titer >=LLOQ	Before Inj1:PMB2001[A56]1:8; N=350,348,355,231,107	17.8 percentage of participants
Group 5: rLP2086(2-,6- Month)+ Saline(0-,1- Month)	Percentage of Participants Achieving hSBA Titer >=LLOQ	1M aft Inj4:PMB80[A22]1:8; N=360,357,369,234,111	91.9 percentage of participants
Group 5: rLP2086(2-,6- Month)+ Saline(0-,1- Month)	Percentage of Participants Achieving hSBA Titer >=LLOQ	1M aft Inj4:PMB2707[B44]1:8; N=356,352,356,230,111	73.0 percentage of participants
Group 5: rLP2086(2-,6- Month)+ Saline(0-,1- Month)	Percentage of Participants Achieving hSBA Titer >=LLOQ	1M aft Inj3:PMB2707[B44]1:8; N=333,331,341,234,105	23.8 percentage of participants
Group 5: rLP2086(2-,6- Month)+ Saline(0-,1- Month)	Percentage of Participants Achieving hSBA Titer >=LLOQ	1M aft Inj2:PMB80[A22]1:8; N=351,345,351,224,110	28.2 percentage of participants
Group 5: rLP2086(2-,6- Month)+ Saline(0-,1- Month)	Percentage of Participants Achieving hSBA Titer >=LLOQ	1M aft Inj4:PMB2948[B24]1:8; N=354,354,359,228,110	69.1 percentage of participants
Group 5: rLP2086(2-,6- Month)+ Saline(0-,1- Month)	Percentage of Participants Achieving hSBA Titer >=LLOQ	1M aft Inj3:PMB2948[B24]1:8; N=328,337,340,237,102	56.9 percentage of participants
Group 5: rLP2086(2-,6- Month)+ Saline(0-,1- Month)	Percentage of Participants Achieving hSBA Titer >=LLOQ	1M aft Inj2:PMB2948[B24]1:8; N=344,345,352,223,110	18.2 percentage of participants
Group 5: rLP2086(2-,6- Month)+ Saline(0-,1- Month)	Percentage of Participants Achieving hSBA Titer >=LLOQ	Before Inj1: PMB80[A22] 1:8; N=356,352,364,235,108	25.0 percentage of participants

Secondary

Percentage of Participants Achieving hSBA Titer >=LLOQ: Group 3 Participants

Time frame: 1 month after Injection 4

Population: The number of participants shown for each test strain represents the number with valid and determinant assay result for that strain.

Arm	Measure	Group	Value (NUMBER)
Group 1:rLP2086(0-,1-,6- Month)+Saline(2- Month)	Percentage of Participants Achieving hSBA Titer >=LLOQ: Group 3 Participants	PMB80 [A22] 1:8 (N=369)	93.5 percentage of participants
Group 1:rLP2086(0-,1-,6- Month)+Saline(2- Month)	Percentage of Participants Achieving hSBA Titer >=LLOQ: Group 3 Participants	PMB2001 [A56] 1: 8 (N=370)	98.4 percentage of participants
Group 1:rLP2086(0-,1-,6- Month)+Saline(2- Month)	Percentage of Participants Achieving hSBA Titer >=LLOQ: Group 3 Participants	PMB2948 [B24] 1:8 (N=359)	81.1 percentage of participants
Group 1:rLP2086(0-,1-,6- Month)+Saline(2- Month)	Percentage of Participants Achieving hSBA Titer >=LLOQ: Group 3 Participants	PMB2707 [B44] 1:8 (N=356)	77.5 percentage of participants

Secondary

Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level

Time frame: Before Injection 1, 1 Month after Injection 2, 3, 4

Population: The number of participants shown for each test strain represents the number with valid and determinant assay result for that strain.

Arm	Measure	Group	Value (NUMBER)
Group 1:rLP2086(0-,1-,6- Month)+Saline(2- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	Before Inj1:PMB2001[A56] 1:4;N=350,348,355,231,107	25.1 percentage of participants
Group 1:rLP2086(0-,1-,6- Month)+Saline(2- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	Before Inj1:PMB80[A22] 1:16; N=356,352,364,235,108	27.2 percentage of participants
Group 1:rLP2086(0-,1-,6- Month)+Saline(2- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	Before Inj1:PMB80[A22] 1:32; N=356,352,364,235,108	18.3 percentage of participants
Group 1:rLP2086(0-,1-,6- Month)+Saline(2- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	Before Inj1:PMB80[A22] 1:64; N=356,352,364,235,108	7.6 percentage of participants
Group 1:rLP2086(0-,1-,6- Month)+Saline(2- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	Before Inj1:PMB80[A22]1:128; N=356,352,364,235,108	1.4 percentage of participants
Group 1:rLP2086(0-,1-,6- Month)+Saline(2- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	1M aft Inj2:PMB80[A22] 1:4; N=351,345,351,224,110	74.9 percentage of participants
Group 1:rLP2086(0-,1-,6- Month)+Saline(2- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	1M aft Inj2:PMB80[A22] 1:16; N=351,345,351,224,110	73.5 percentage of participants
Group 1:rLP2086(0-,1-,6- Month)+Saline(2- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	1M aft Inj2:PMB80[A22] 1:32; N=351,345,351,224,110	58.4 percentage of participants
Group 1:rLP2086(0-,1-,6- Month)+Saline(2- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	1M aft Inj2:PMB80[A22] 1:64; N=351,345,351,224,110	30.8 percentage of participants
Group 1:rLP2086(0-,1-,6- Month)+Saline(2- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	1M aft Inj2:PMB80[A22]1:128; N=351,345,351,224,110	14.8 percentage of participants
Group 1:rLP2086(0-,1-,6- Month)+Saline(2- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	1M aft Inj3:PMB80[A22] 1:4; N=332,344,340,238,102	63.6 percentage of participants
Group 1:rLP2086(0-,1-,6- Month)+Saline(2- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	1M aft Inj3:PMB80[A22]1:16; N=332,344,340,238,102	62.3 percentage of participants
Group 1:rLP2086(0-,1-,6- Month)+Saline(2- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	1M aft Inj3:PMB80[A22]1:32; N=332,344,340,238,102	47.3 percentage of participants
Group 1:rLP2086(0-,1-,6- Month)+Saline(2- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	1M aft Inj3:PMB80[A22]1:64; N=332,344,340,238,102	22.3 percentage of participants
Group 1:rLP2086(0-,1-,6- Month)+Saline(2- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	1M aft Inj3:PMB80[A22]1:128; N=332,344,340,238,102	11.7 percentage of participants
Group 1:rLP2086(0-,1-,6- Month)+Saline(2- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	1M aft Inj4:PMB80[A22] 1:4; N=360,357,369,234,111	91.9 percentage of participants
Group 1:rLP2086(0-,1-,6- Month)+Saline(2- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	1M aft Inj4:PMB80[A22] 1:16; N=360,357,369,234,111	91.4 percentage of participants
Group 1:rLP2086(0-,1-,6- Month)+Saline(2- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	1M aft Inj4:PMB80[A22] 1:32; N=360,357,369,234,111	84.2 percentage of participants
Group 1:rLP2086(0-,1-,6- Month)+Saline(2- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	1M aft Inj4:PMB80[A22] 1:64; N=360,357,369,234,111	61.9 percentage of participants
Group 1:rLP2086(0-,1-,6- Month)+Saline(2- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	1M aft Inj4:PMB80[A22]1:128; N=360,357,369,234,111	31.7 percentage of participants
Group 1:rLP2086(0-,1-,6- Month)+Saline(2- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	Before Inj1:PMB80[A22] 1:4; N=356,352,364,235,108	28.9 percentage of participants
Group 1:rLP2086(0-,1-,6- Month)+Saline(2- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	Before Inj1:PMB2001[A56]1:16;N=350,348,355,231,107	20.0 percentage of participants
Group 1:rLP2086(0-,1-,6- Month)+Saline(2- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	Before Inj1:PMB2001[A56]1:32;N=350,348,355,231,107	18.0 percentage of participants
Group 1:rLP2086(0-,1-,6- Month)+Saline(2- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	Before Inj1:PMB2001[A56]1:64;N=350,348,355,231,107	11.7 percentage of participants
Group 1:rLP2086(0-,1-,6- Month)+Saline(2- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	Before Inj1: PMB2001 1:128;N=350,348,355,231,107	4.3 percentage of participants
Group 1:rLP2086(0-,1-,6- Month)+Saline(2- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	1M aft Inj2:PMB2001[A56] 1:4;N=353,329,335,218,102	96.6 percentage of participants
Group 1:rLP2086(0-,1-,6- Month)+Saline(2- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	1M aft Inj2:PMB2001[A56]1:16;N=353,329,335,218,102	96.3 percentage of participants
Group 1:rLP2086(0-,1-,6- Month)+Saline(2- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	1M aft Inj2:PMB2001[A56]1:32;N=353,329,335,218,102	87.8 percentage of participants
Group 1:rLP2086(0-,1-,6- Month)+Saline(2- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	1M aft Inj2:PMB2001[A56]1:64;N=353,329,335,218,102	72.8 percentage of participants
Group 1:rLP2086(0-,1-,6- Month)+Saline(2- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	1M aft Inj2:PMB2001 1:128;N=353,329,335,218,102	41.1 percentage of participants
Group 1:rLP2086(0-,1-,6- Month)+Saline(2- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	1M aft Inj3:PMB2001[A56] 1:4;N=329,339,320,240,102	91.5 percentage of participants
Group 1:rLP2086(0-,1-,6- Month)+Saline(2- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	1M aft Inj3:PMB2001[A56]1:16;N=329,339,320,240,102	87.8 percentage of participants
Group 1:rLP2086(0-,1-,6- Month)+Saline(2- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	1M aft Inj3:PMB2001[A56]1:32;N=329,339,320,240,102	79.9 percentage of participants
Group 1:rLP2086(0-,1-,6- Month)+Saline(2- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	1M aft Inj3:PMB2001[A56]1:64;N=329,339,320,240,102	52.9 percentage of participants
Group 1:rLP2086(0-,1-,6- Month)+Saline(2- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	1M aft Inj3:PMB2001 1:128;N=329,339,320,240,102	26.7 percentage of participants
Group 1:rLP2086(0-,1-,6- Month)+Saline(2- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	1M aft Inj4:PMB2001[A56] 1:4;N=362,359,370,228,113	99.7 percentage of participants
Group 1:rLP2086(0-,1-,6- Month)+Saline(2- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	1M aft Inj4:PMB2001[A56]1:16;N=362,359,370,228,113	99.2 percentage of participants
Group 1:rLP2086(0-,1-,6- Month)+Saline(2- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	1M aft Inj4:PMB2001[A56]1:32;N=362,359,370,228,113	95.3 percentage of participants
Group 1:rLP2086(0-,1-,6- Month)+Saline(2- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	1M aft Inj4:PMB2001[A56]1:64;N=362,359,370,228,113	87.8 percentage of participants
Group 1:rLP2086(0-,1-,6- Month)+Saline(2- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	1M aft Inj4:PMB2001 1:128;N=362,359,370,228,113	72.4 percentage of participants
Group 1:rLP2086(0-,1-,6- Month)+Saline(2- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	Before Inj1:PMB2948[B24]1:4;N=362,356,369,241,112	18.5 percentage of participants
Group 1:rLP2086(0-,1-,6- Month)+Saline(2- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	Before Inj1:PMB2948[B24]1:16;N=362,356,369,241,112	12.7 percentage of participants
Group 1:rLP2086(0-,1-,6- Month)+Saline(2- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	Before Inj1:PMB2948[B24]1:32;N=362,356,369,241,112	7.2 percentage of participants
Group 1:rLP2086(0-,1-,6- Month)+Saline(2- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	Before Inj1:PMB2948[B24]1:64;N=362,356,369,241,112	2.8 percentage of participants
Group 1:rLP2086(0-,1-,6- Month)+Saline(2- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	Before Inj1:PMB2948 1:128;N=362,356,369,241,112	1.4 percentage of participants
Group 1:rLP2086(0-,1-,6- Month)+Saline(2- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	1M aft Inj2:PMB2948[B24]1:4;N=344,345,352,223,110	66.3 percentage of participants
Group 1:rLP2086(0-,1-,6- Month)+Saline(2- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	1M aft Inj2:PMB2948[B24]1:16;N=344,345,352,223,110	57.6 percentage of participants
Group 1:rLP2086(0-,1-,6- Month)+Saline(2- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	1M aft Inj2:PMB2948[B24]1:32;N=344,345,352,223,110	34.9 percentage of participants
Group 1:rLP2086(0-,1-,6- Month)+Saline(2- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	1M aft Inj2:PMB2948[B24]1:64;N=344,345,352,223,110	14.0 percentage of participants
Group 1:rLP2086(0-,1-,6- Month)+Saline(2- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	1M aft Inj2:PMB2948 1:128;N=344,345,352,223,110	6.1 percentage of participants
Group 1:rLP2086(0-,1-,6- Month)+Saline(2- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	1M aft Inj3:PMB2948[B24]1:4;N=328,337,340,237,102	52.1 percentage of participants
Group 1:rLP2086(0-,1-,6- Month)+Saline(2- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	1M aft Inj3:PMB2948[B24]1:16;N=328,337,340,237,102	45.1 percentage of participants
Group 1:rLP2086(0-,1-,6- Month)+Saline(2- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	1M aft Inj3:PMB2948[B24]1:32;N=328,337,340,237,102	23.8 percentage of participants
Group 1:rLP2086(0-,1-,6- Month)+Saline(2- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	1M aft Inj3:PMB2948[B24]1:64;N=328,337,340,237,102	15.5 percentage of participants
Group 1:rLP2086(0-,1-,6- Month)+Saline(2- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	1M aft Inj3:PMB2948 1:128;N=328,337,340,237,102	6.7 percentage of participants
Group 1:rLP2086(0-,1-,6- Month)+Saline(2- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	1M aft Inj4:PMB2948[B24]1:4;N=354,354,359,228,110	90.1 percentage of participants
Group 1:rLP2086(0-,1-,6- Month)+Saline(2- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	1M aft Inj4:PMB2948[B24]1:16;N=354,354,359,228,110	82.8 percentage of participants
Group 1:rLP2086(0-,1-,6- Month)+Saline(2- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	1M aft Inj4:PMB2948[B24]1:32;N=354,354,359,228,110	60.7 percentage of participants
Group 1:rLP2086(0-,1-,6- Month)+Saline(2- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	1M aft Inj4:PMB2948[B24]1:64;N=354,354,359,228,110	33.3 percentage of participants
Group 1:rLP2086(0-,1-,6- Month)+Saline(2- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	1M aft Inj4:PMB2948 1:128;N=354,354,359,228,110	13.0 percentage of participants
Group 1:rLP2086(0-,1-,6- Month)+Saline(2- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	Before Inj1:PMB2707[B44]1:4;N=363,357,370,241,113	7.7 percentage of participants
Group 1:rLP2086(0-,1-,6- Month)+Saline(2- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	Before Inj1:PMB2707[B44]1:16;N=363,357,370,241,113	3.6 percentage of participants
Group 1:rLP2086(0-,1-,6- Month)+Saline(2- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	Before Inj1:PMB2707[B44]1:32;N=363,357,370,241,113	3.0 percentage of participants
Group 1:rLP2086(0-,1-,6- Month)+Saline(2- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	Before Inj1:PMB2707[B44]1:64;N=363,357,370,241,113	0.6 percentage of participants
Group 1:rLP2086(0-,1-,6- Month)+Saline(2- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	Before Inj1:PMB2707 1:128;N=363,357,370,241,113	0.0 percentage of participants
Group 1:rLP2086(0-,1-,6- Month)+Saline(2- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	1M aft Inj2:PMB2707[B44]1:4;N=341,345,349,225,111	57.5 percentage of participants
Group 1:rLP2086(0-,1-,6- Month)+Saline(2- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	1M aft Inj2:PMB2707[B44]1:16;N=341,345,349,225,111	47.2 percentage of participants
Group 1:rLP2086(0-,1-,6- Month)+Saline(2- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	1M aft Inj2:PMB2707[B44]1:32;N=341,345,349,225,111	32.0 percentage of participants
Group 1:rLP2086(0-,1-,6- Month)+Saline(2- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	1M aft Inj2:PMB2707[B44]1:64;N=341,345,349,225,111	18.8 percentage of participants
Group 1:rLP2086(0-,1-,6- Month)+Saline(2- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	1M aft Inj2:PMB2707 1:128;N=341,345,349,225,111	10.0 percentage of participants
Group 1:rLP2086(0-,1-,6- Month)+Saline(2- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	1M aft Inj3:PMB2707[B44]1:4;N=333,331,341,234,105	39.0 percentage of participants
Group 1:rLP2086(0-,1-,6- Month)+Saline(2- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	1M aft Inj3:PMB2707[B44]1:16;N=333,331,341,234,105	30.3 percentage of participants
Group 1:rLP2086(0-,1-,6- Month)+Saline(2- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	1M aft Inj3:PMB2707[B44]1:32;N=333,331,341,234,105	18.6 percentage of participants
Group 1:rLP2086(0-,1-,6- Month)+Saline(2- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	1M aft Inj3:PMB2707[B44]1:64;N=333,331,341,234,105	11.4 percentage of participants
Group 1:rLP2086(0-,1-,6- Month)+Saline(2- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	1M aft Inj3:PMB2707 1:128;N=333,331,341,234,105	6.3 percentage of participants
Group 1:rLP2086(0-,1-,6- Month)+Saline(2- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	1M aft Inj4:PMB2707[B44]1:4;N=356,352,356,230,111	89.3 percentage of participants
Group 1:rLP2086(0-,1-,6- Month)+Saline(2- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	1M aft Inj4:PMB2707[B44]1:16;N=356,352,356,230,111	84.8 percentage of participants
Group 1:rLP2086(0-,1-,6- Month)+Saline(2- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	1M aft Inj4:PMB2707[B44]1:32;N=356,352,356,230,111	68.5 percentage of participants
Group 1:rLP2086(0-,1-,6- Month)+Saline(2- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	1M aft Inj4:PMB2707[B44]1:64;N=356,352,356,230,111	46.6 percentage of participants
Group 1:rLP2086(0-,1-,6- Month)+Saline(2- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	1M aft Inj4:PMB2707 1:128;N=356,352,356,230,111	27.5 percentage of participants
Group 2:rLP2086(0-,2-,6- Month)+Saline(1- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	1M aft Inj2:PMB2707[B44]1:32;N=341,345,349,225,111	9.9 percentage of participants
Group 2:rLP2086(0-,2-,6- Month)+Saline(1- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	1M aft Inj3:PMB2001[A56]1:32;N=329,339,320,240,102	94.1 percentage of participants
Group 2:rLP2086(0-,2-,6- Month)+Saline(1- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	1M aft Inj2:PMB80[A22] 1:32; N=351,345,351,224,110	28.7 percentage of participants
Group 2:rLP2086(0-,2-,6- Month)+Saline(1- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	1M aft Inj2:PMB2948[B24]1:16;N=344,345,352,223,110	32.8 percentage of participants
Group 2:rLP2086(0-,2-,6- Month)+Saline(1- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	1M aft Inj3:PMB2707[B44]1:64;N=333,331,341,234,105	22.7 percentage of participants
Group 2:rLP2086(0-,2-,6- Month)+Saline(1- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	1M aft Inj2:PMB2948[B24]1:4;N=344,345,352,223,110	42.3 percentage of participants
Group 2:rLP2086(0-,2-,6- Month)+Saline(1- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	1M aft Inj3:PMB2001[A56]1:64;N=329,339,320,240,102	79.1 percentage of participants
Group 2:rLP2086(0-,2-,6- Month)+Saline(1- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	Before Inj1:PMB2001[A56] 1:4;N=350,348,355,231,107	22.1 percentage of participants
Group 2:rLP2086(0-,2-,6- Month)+Saline(1- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	Before Inj1:PMB2948 1:128;N=362,356,369,241,112	0.8 percentage of participants
Group 2:rLP2086(0-,2-,6- Month)+Saline(1- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	Before Inj1:PMB2948[B24]1:64;N=362,356,369,241,112	3.1 percentage of participants
Group 2:rLP2086(0-,2-,6- Month)+Saline(1- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	Before Inj1:PMB2948[B24]1:32;N=362,356,369,241,112	6.2 percentage of participants
Group 2:rLP2086(0-,2-,6- Month)+Saline(1- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	1M aft Inj3:PMB2001 1:128;N=329,339,320,240,102	50.4 percentage of participants
Group 2:rLP2086(0-,2-,6- Month)+Saline(1- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	1M aft Inj4:PMB80[A22] 1:32; N=360,357,369,234,111	86.6 percentage of participants
Group 2:rLP2086(0-,2-,6- Month)+Saline(1- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	Before Inj1:PMB2948[B24]1:16;N=362,356,369,241,112	11.5 percentage of participants
Group 2:rLP2086(0-,2-,6- Month)+Saline(1- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	1M aft Inj3:PMB2707[B44]1:32;N=333,331,341,234,105	39.0 percentage of participants
Group 2:rLP2086(0-,2-,6- Month)+Saline(1- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	1M aft Inj4:PMB2707[B44]1:64;N=356,352,356,230,111	42.3 percentage of participants
Group 2:rLP2086(0-,2-,6- Month)+Saline(1- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	1M aft Inj4:PMB2001[A56] 1:4;N=362,359,370,228,113	99.2 percentage of participants
Group 2:rLP2086(0-,2-,6- Month)+Saline(1- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	1M aft Inj2:PMB80[A22] 1:16; N=351,345,351,224,110	45.8 percentage of participants
Group 2:rLP2086(0-,2-,6- Month)+Saline(1- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	Before Inj1:PMB2948[B24]1:4;N=362,356,369,241,112	15.4 percentage of participants
Group 2:rLP2086(0-,2-,6- Month)+Saline(1- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	1M aft Inj4:PMB2001 1:128;N=362,359,370,228,113	73.5 percentage of participants
Group 2:rLP2086(0-,2-,6- Month)+Saline(1- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	1M aft Inj3:PMB2707[B44]1:16;N=333,331,341,234,105	58.6 percentage of participants
Group 2:rLP2086(0-,2-,6- Month)+Saline(1- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	1M aft Inj4:PMB2001[A56]1:16;N=362,359,370,228,113	98.9 percentage of participants
Group 2:rLP2086(0-,2-,6- Month)+Saline(1- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	1M aft Inj2:PMB2707[B44]1:4;N=341,345,349,225,111	17.7 percentage of participants
Group 2:rLP2086(0-,2-,6- Month)+Saline(1- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	1M aft Inj4:PMB2001[A56]1:64;N=362,359,370,228,113	91.1 percentage of participants
Group 2:rLP2086(0-,2-,6- Month)+Saline(1- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	1M aft Inj4:PMB2001[A56]1:32;N=362,359,370,228,113	96.1 percentage of participants
Group 2:rLP2086(0-,2-,6- Month)+Saline(1- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	1M aft Inj2:PMB2707[B44]1:64;N=341,345,349,225,111	4.1 percentage of participants
Group 2:rLP2086(0-,2-,6- Month)+Saline(1- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	Before Inj1:PMB2001[A56]1:16;N=350,348,355,231,107	18.1 percentage of participants
Group 2:rLP2086(0-,2-,6- Month)+Saline(1- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	1M aft Inj4:PMB80[A22] 1:4; N=360,357,369,234,111	95.0 percentage of participants
Group 2:rLP2086(0-,2-,6- Month)+Saline(1- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	1M aft Inj2:PMB80[A22] 1:4; N=351,345,351,224,110	47.8 percentage of participants
Group 2:rLP2086(0-,2-,6- Month)+Saline(1- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	Before Inj1:PMB80[A22]1:128; N=356,352,364,235,108	2.3 percentage of participants
Group 2:rLP2086(0-,2-,6- Month)+Saline(1- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	1M aft Inj3:PMB80[A22]1:64; N=332,344,340,238,102	35.8 percentage of participants
Group 2:rLP2086(0-,2-,6- Month)+Saline(1- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	Before Inj1:PMB2001[A56]1:32;N=350,348,355,231,107	14.1 percentage of participants
Group 2:rLP2086(0-,2-,6- Month)+Saline(1- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	1M aft Inj3:PMB80[A22]1:32; N=332,344,340,238,102	69.5 percentage of participants
Group 2:rLP2086(0-,2-,6- Month)+Saline(1- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	Before Inj1:PMB80[A22] 1:64; N=356,352,364,235,108	6.5 percentage of participants
Group 2:rLP2086(0-,2-,6- Month)+Saline(1- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	Before Inj1:PMB80[A22] 1:32; N=356,352,364,235,108	14.5 percentage of participants
Group 2:rLP2086(0-,2-,6- Month)+Saline(1- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	Before Inj1:PMB80[A22] 1:16; N=356,352,364,235,108	20.5 percentage of participants
Group 2:rLP2086(0-,2-,6- Month)+Saline(1- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	Before Inj1:PMB2001[A56]1:64;N=350,348,355,231,107	7.5 percentage of participants
Group 2:rLP2086(0-,2-,6- Month)+Saline(1- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	1M aft Inj3:PMB80[A22]1:16; N=332,344,340,238,102	88.1 percentage of participants
Group 2:rLP2086(0-,2-,6- Month)+Saline(1- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	Before Inj1:PMB2707 1:128;N=363,357,370,241,113	0.3 percentage of participants
Group 2:rLP2086(0-,2-,6- Month)+Saline(1- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	Before Inj1:PMB80[A22] 1:4; N=356,352,364,235,108	23.9 percentage of participants
Group 2:rLP2086(0-,2-,6- Month)+Saline(1- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	Before Inj1:PMB2707[B44]1:64;N=363,357,370,241,113	1.4 percentage of participants
Group 2:rLP2086(0-,2-,6- Month)+Saline(1- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	Before Inj1: PMB2001 1:128;N=350,348,355,231,107	2.3 percentage of participants
Group 2:rLP2086(0-,2-,6- Month)+Saline(1- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	1M aft Inj4:PMB80[A22] 1:64; N=360,357,369,234,111	63.9 percentage of participants
Group 2:rLP2086(0-,2-,6- Month)+Saline(1- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	Before Inj1:PMB2707[B44]1:32;N=363,357,370,241,113	2.5 percentage of participants
Group 2:rLP2086(0-,2-,6- Month)+Saline(1- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	Before Inj1:PMB2707[B44]1:16;N=363,357,370,241,113	5.0 percentage of participants
Group 2:rLP2086(0-,2-,6- Month)+Saline(1- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	1M aft Inj4:PMB2707[B44]1:16;N=356,352,356,230,111	83.8 percentage of participants
Group 2:rLP2086(0-,2-,6- Month)+Saline(1- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	1M aft Inj2:PMB2001[A56] 1:4;N=353,329,335,218,102	61.4 percentage of participants
Group 2:rLP2086(0-,2-,6- Month)+Saline(1- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	1M aft Inj3:PMB80[A22]1:128; N=332,344,340,238,102	14.8 percentage of participants
Group 2:rLP2086(0-,2-,6- Month)+Saline(1- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	Before Inj1:PMB2707[B44]1:4;N=363,357,370,241,113	7.8 percentage of participants
Group 2:rLP2086(0-,2-,6- Month)+Saline(1- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	1M aft Inj4:PMB2707 1:128;N=356,352,356,230,111	22.7 percentage of participants
Group 2:rLP2086(0-,2-,6- Month)+Saline(1- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	1M aft Inj2:PMB2707 1:128;N=341,345,349,225,111	1.7 percentage of participants
Group 2:rLP2086(0-,2-,6- Month)+Saline(1- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	1M aft Inj2:PMB2001[A56]1:16;N=353,329,335,218,102	55.0 percentage of participants
Group 2:rLP2086(0-,2-,6- Month)+Saline(1- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	1M aft Inj2:PMB2707[B44]1:16;N=341,345,349,225,111	13.6 percentage of participants
Group 2:rLP2086(0-,2-,6- Month)+Saline(1- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	1M aft Inj4:PMB2948 1:128;N=354,354,359,228,110	10.5 percentage of participants
Group 2:rLP2086(0-,2-,6- Month)+Saline(1- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	1M aft Inj4:PMB2948[B24]1:64;N=354,354,359,228,110	26.6 percentage of participants
Group 2:rLP2086(0-,2-,6- Month)+Saline(1- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	1M aft Inj3:PMB80[A22] 1:4; N=332,344,340,238,102	88.7 percentage of participants
Group 2:rLP2086(0-,2-,6- Month)+Saline(1- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	1M aft Inj2:PMB2001[A56]1:32;N=353,329,335,218,102	48.0 percentage of participants
Group 2:rLP2086(0-,2-,6- Month)+Saline(1- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	1M aft Inj4:PMB2707[B44]1:32;N=356,352,356,230,111	65.3 percentage of participants
Group 2:rLP2086(0-,2-,6- Month)+Saline(1- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	1M aft Inj4:PMB2948[B24]1:32;N=354,354,359,228,110	56.2 percentage of participants
Group 2:rLP2086(0-,2-,6- Month)+Saline(1- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	1M aft Inj4:PMB2948[B24]1:16;N=354,354,359,228,110	83.6 percentage of participants
Group 2:rLP2086(0-,2-,6- Month)+Saline(1- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	1M aft Inj4:PMB2707[B44]1:4;N=356,352,356,230,111	87.8 percentage of participants
Group 2:rLP2086(0-,2-,6- Month)+Saline(1- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	1M aft Inj2:PMB2001[A56]1:64;N=353,329,335,218,102	27.4 percentage of participants
Group 2:rLP2086(0-,2-,6- Month)+Saline(1- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	1M aft Inj4:PMB80[A22]1:128; N=360,357,369,234,111	32.5 percentage of participants
Group 2:rLP2086(0-,2-,6- Month)+Saline(1- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	1M aft Inj4:PMB2948[B24]1:4;N=354,354,359,228,110	90.1 percentage of participants
Group 2:rLP2086(0-,2-,6- Month)+Saline(1- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	1M aft Inj3:PMB2948 1:128;N=328,337,340,237,102	6.5 percentage of participants
Group 2:rLP2086(0-,2-,6- Month)+Saline(1- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	1M aft Inj3:PMB2948[B24]1:64;N=328,337,340,237,102	13.6 percentage of participants
Group 2:rLP2086(0-,2-,6- Month)+Saline(1- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	1M aft Inj2:PMB2001 1:128;N=353,329,335,218,102	14.3 percentage of participants
Group 2:rLP2086(0-,2-,6- Month)+Saline(1- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	1M aft Inj4:PMB80[A22] 1:16; N=360,357,369,234,111	95.0 percentage of participants
Group 2:rLP2086(0-,2-,6- Month)+Saline(1- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	1M aft Inj3:PMB2948[B24]1:32;N=328,337,340,237,102	32.0 percentage of participants
Group 2:rLP2086(0-,2-,6- Month)+Saline(1- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	1M aft Inj3:PMB2948[B24]1:16;N=328,337,340,237,102	63.5 percentage of participants
Group 2:rLP2086(0-,2-,6- Month)+Saline(1- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	1M aft Inj3:PMB2707 1:128;N=333,331,341,234,105	7.9 percentage of participants
Group 2:rLP2086(0-,2-,6- Month)+Saline(1- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	1M aft Inj3:PMB2001[A56] 1:4;N=329,339,320,240,102	98.5 percentage of participants
Group 2:rLP2086(0-,2-,6- Month)+Saline(1- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	1M aft Inj2:PMB80[A22]1:128; N=351,345,351,224,110	5.2 percentage of participants
Group 2:rLP2086(0-,2-,6- Month)+Saline(1- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	1M aft Inj3:PMB2948[B24]1:4;N=328,337,340,237,102	72.1 percentage of participants
Group 2:rLP2086(0-,2-,6- Month)+Saline(1- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	1M aft Inj2:PMB2948 1:128;N=344,345,352,223,110	3.5 percentage of participants
Group 2:rLP2086(0-,2-,6- Month)+Saline(1- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	1M aft Inj3:PMB2707[B44]1:4;N=333,331,341,234,105	65.9 percentage of participants
Group 2:rLP2086(0-,2-,6- Month)+Saline(1- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	1M aft Inj3:PMB2001[A56]1:16;N=329,339,320,240,102	97.9 percentage of participants
Group 2:rLP2086(0-,2-,6- Month)+Saline(1- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	1M aft Inj2:PMB80[A22] 1:64; N=351,345,351,224,110	14.5 percentage of participants
Group 2:rLP2086(0-,2-,6- Month)+Saline(1- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	1M aft Inj2:PMB2948[B24]1:64;N=344,345,352,223,110	9.0 percentage of participants
Group 2:rLP2086(0-,2-,6- Month)+Saline(1- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	1M aft Inj2:PMB2948[B24]1:32;N=344,345,352,223,110	18.6 percentage of participants
Group 3: rLP2086(0-,6- Month)+Saline(1-,2- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	1M aft Inj3:PMB2707[B44]1:4;N=333,331,341,234,105	15.5 percentage of participants
Group 3: rLP2086(0-,6- Month)+Saline(1-,2- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	1M aft Inj4:PMB80[A22] 1:16; N=360,357,369,234,111	93.2 percentage of participants
Group 3: rLP2086(0-,6- Month)+Saline(1-,2- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	1M aft Inj2:PMB2707[B44]1:32;N=341,345,349,225,111	8.3 percentage of participants
Group 3: rLP2086(0-,6- Month)+Saline(1-,2- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	1M aft Inj4:PMB80[A22] 1:32; N=360,357,369,234,111	81.8 percentage of participants
Group 3: rLP2086(0-,6- Month)+Saline(1-,2- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	1M aft Inj4:PMB80[A22] 1:64; N=360,357,369,234,111	53.9 percentage of participants
Group 3: rLP2086(0-,6- Month)+Saline(1-,2- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	1M aft Inj4:PMB80[A22]1:128; N=360,357,369,234,111	25.7 percentage of participants
Group 3: rLP2086(0-,6- Month)+Saline(1-,2- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	Before Inj1:PMB2001[A56] 1:4;N=350,348,355,231,107	25.1 percentage of participants
Group 3: rLP2086(0-,6- Month)+Saline(1-,2- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	Before Inj1:PMB2001[A56]1:16;N=350,348,355,231,107	20.3 percentage of participants
Group 3: rLP2086(0-,6- Month)+Saline(1-,2- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	1M aft Inj2:PMB2707[B44]1:64;N=341,345,349,225,111	5.2 percentage of participants
Group 3: rLP2086(0-,6- Month)+Saline(1-,2- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	Before Inj1:PMB2001[A56]1:32;N=350,348,355,231,107	17.2 percentage of participants
Group 3: rLP2086(0-,6- Month)+Saline(1-,2- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	Before Inj1:PMB2001[A56]1:64;N=350,348,355,231,107	10.7 percentage of participants
Group 3: rLP2086(0-,6- Month)+Saline(1-,2- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	Before Inj1: PMB2001 1:128;N=350,348,355,231,107	3.7 percentage of participants
Group 3: rLP2086(0-,6- Month)+Saline(1-,2- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	1M aft Inj2:PMB2001[A56] 1:4;N=353,329,335,218,102	63.3 percentage of participants
Group 3: rLP2086(0-,6- Month)+Saline(1-,2- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	1M aft Inj2:PMB2001[A56]1:16;N=353,329,335,218,102	57.9 percentage of participants
Group 3: rLP2086(0-,6- Month)+Saline(1-,2- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	1M aft Inj2:PMB2707 1:128;N=341,345,349,225,111	3.7 percentage of participants
Group 3: rLP2086(0-,6- Month)+Saline(1-,2- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	1M aft Inj2:PMB2001[A56]1:32;N=353,329,335,218,102	50.1 percentage of participants
Group 3: rLP2086(0-,6- Month)+Saline(1-,2- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	1M aft Inj2:PMB2001[A56]1:64;N=353,329,335,218,102	31.0 percentage of participants
Group 3: rLP2086(0-,6- Month)+Saline(1-,2- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	1M aft Inj2:PMB2001 1:128;N=353,329,335,218,102	14.9 percentage of participants
Group 3: rLP2086(0-,6- Month)+Saline(1-,2- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	1M aft Inj3:PMB2001[A56] 1:4;N=329,339,320,240,102	54.4 percentage of participants
Group 3: rLP2086(0-,6- Month)+Saline(1-,2- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	1M aft Inj3:PMB2001[A56]1:16;N=329,339,320,240,102	50.0 percentage of participants
Group 3: rLP2086(0-,6- Month)+Saline(1-,2- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	1M aft Inj3:PMB2001[A56]1:32;N=329,339,320,240,102	43.8 percentage of participants
Group 3: rLP2086(0-,6- Month)+Saline(1-,2- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	1M aft Inj3:PMB2001[A56]1:64;N=329,339,320,240,102	28.4 percentage of participants
Group 3: rLP2086(0-,6- Month)+Saline(1-,2- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	1M aft Inj3:PMB2001 1:128;N=329,339,320,240,102	13.1 percentage of participants
Group 3: rLP2086(0-,6- Month)+Saline(1-,2- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	1M aft Inj4:PMB2001[A56] 1:4;N=362,359,370,228,113	98.9 percentage of participants
Group 3: rLP2086(0-,6- Month)+Saline(1-,2- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	1M aft Inj4:PMB2001[A56]1:16;N=362,359,370,228,113	98.4 percentage of participants
Group 3: rLP2086(0-,6- Month)+Saline(1-,2- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	1M aft Inj3:PMB2707[B44]1:16;N=333,331,341,234,105	10.9 percentage of participants
Group 3: rLP2086(0-,6- Month)+Saline(1-,2- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	1M aft Inj4:PMB2001[A56]1:32;N=362,359,370,228,113	94.6 percentage of participants
Group 3: rLP2086(0-,6- Month)+Saline(1-,2- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	1M aft Inj4:PMB2001[A56]1:64;N=362,359,370,228,113	83.8 percentage of participants
Group 3: rLP2086(0-,6- Month)+Saline(1-,2- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	1M aft Inj4:PMB2001 1:128;N=362,359,370,228,113	65.9 percentage of participants
Group 3: rLP2086(0-,6- Month)+Saline(1-,2- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	1M aft Inj4:PMB2707[B44]1:64;N=356,352,356,230,111	27.8 percentage of participants
Group 3: rLP2086(0-,6- Month)+Saline(1-,2- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	Before Inj1:PMB2948[B24]1:4;N=362,356,369,241,112	14.4 percentage of participants
Group 3: rLP2086(0-,6- Month)+Saline(1-,2- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	Before Inj1:PMB2948[B24]1:16;N=362,356,369,241,112	10.8 percentage of participants
Group 3: rLP2086(0-,6- Month)+Saline(1-,2- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	1M aft Inj3:PMB2707[B44]1:32;N=333,331,341,234,105	5.9 percentage of participants
Group 3: rLP2086(0-,6- Month)+Saline(1-,2- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	Before Inj1:PMB2948[B24]1:32;N=362,356,369,241,112	6.0 percentage of participants
Group 3: rLP2086(0-,6- Month)+Saline(1-,2- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	Before Inj1:PMB2948[B24]1:64;N=362,356,369,241,112	2.2 percentage of participants
Group 3: rLP2086(0-,6- Month)+Saline(1-,2- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	Before Inj1:PMB2948 1:128;N=362,356,369,241,112	0.5 percentage of participants
Group 3: rLP2086(0-,6- Month)+Saline(1-,2- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	1M aft Inj2:PMB2948[B24]1:4;N=344,345,352,223,110	45.7 percentage of participants
Group 3: rLP2086(0-,6- Month)+Saline(1-,2- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	1M aft Inj2:PMB2948[B24]1:16;N=344,345,352,223,110	39.5 percentage of participants
Group 3: rLP2086(0-,6- Month)+Saline(1-,2- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	1M aft Inj3:PMB2707[B44]1:64;N=333,331,341,234,105	3.8 percentage of participants
Group 3: rLP2086(0-,6- Month)+Saline(1-,2- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	1M aft Inj2:PMB2948[B24]1:32;N=344,345,352,223,110	23.3 percentage of participants
Group 3: rLP2086(0-,6- Month)+Saline(1-,2- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	1M aft Inj2:PMB2948[B24]1:64;N=344,345,352,223,110	8.8 percentage of participants
Group 3: rLP2086(0-,6- Month)+Saline(1-,2- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	1M aft Inj2:PMB2948 1:128;N=344,345,352,223,110	2.6 percentage of participants
Group 3: rLP2086(0-,6- Month)+Saline(1-,2- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	1M aft Inj3:PMB2948[B24]1:4;N=328,337,340,237,102	37.6 percentage of participants
Group 3: rLP2086(0-,6- Month)+Saline(1-,2- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	1M aft Inj3:PMB2948[B24]1:16;N=328,337,340,237,102	29.7 percentage of participants
Group 3: rLP2086(0-,6- Month)+Saline(1-,2- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	1M aft Inj3:PMB2707 1:128;N=333,331,341,234,105	2.6 percentage of participants
Group 3: rLP2086(0-,6- Month)+Saline(1-,2- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	1M aft Inj3:PMB2948[B24]1:32;N=328,337,340,237,102	15.9 percentage of participants
Group 3: rLP2086(0-,6- Month)+Saline(1-,2- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	1M aft Inj3:PMB2948[B24]1:64;N=328,337,340,237,102	5.0 percentage of participants
Group 3: rLP2086(0-,6- Month)+Saline(1-,2- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	1M aft Inj3:PMB2948 1:128;N=328,337,340,237,102	2.6 percentage of participants
Group 3: rLP2086(0-,6- Month)+Saline(1-,2- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	1M aft Inj4:PMB2948[B24]1:4;N=354,354,359,228,110	83.0 percentage of participants
Group 3: rLP2086(0-,6- Month)+Saline(1-,2- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	1M aft Inj4:PMB2948[B24]1:16;N=354,354,359,228,110	73.8 percentage of participants
Group 3: rLP2086(0-,6- Month)+Saline(1-,2- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	1M aft Inj4:PMB2707[B44]1:4;N=356,352,356,230,111	78.9 percentage of participants
Group 3: rLP2086(0-,6- Month)+Saline(1-,2- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	1M aft Inj4:PMB2948[B24]1:32;N=354,354,359,228,110	47.1 percentage of participants
Group 3: rLP2086(0-,6- Month)+Saline(1-,2- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	1M aft Inj4:PMB2948[B24]1:64;N=354,354,359,228,110	22.6 percentage of participants
Group 3: rLP2086(0-,6- Month)+Saline(1-,2- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	1M aft Inj4:PMB2948 1:128;N=354,354,359,228,110	7.2 percentage of participants
Group 3: rLP2086(0-,6- Month)+Saline(1-,2- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	Before Inj1:PMB2707[B44]1:4;N=363,357,370,241,113	7.8 percentage of participants
Group 3: rLP2086(0-,6- Month)+Saline(1-,2- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	Before Inj1:PMB2707[B44]1:16;N=363,357,370,241,113	4.9 percentage of participants
Group 3: rLP2086(0-,6- Month)+Saline(1-,2- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	1M aft Inj4:PMB2707[B44]1:16;N=356,352,356,230,111	70.8 percentage of participants
Group 3: rLP2086(0-,6- Month)+Saline(1-,2- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	Before Inj1:PMB2707[B44]1:32;N=363,357,370,241,113	3.5 percentage of participants
Group 3: rLP2086(0-,6- Month)+Saline(1-,2- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	Before Inj1:PMB2707[B44]1:64;N=363,357,370,241,113	1.4 percentage of participants
Group 3: rLP2086(0-,6- Month)+Saline(1-,2- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	Before Inj1:PMB80[A22] 1:4; N=356,352,364,235,108	26.4 percentage of participants
Group 3: rLP2086(0-,6- Month)+Saline(1-,2- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	Before Inj1:PMB80[A22] 1:16; N=356,352,364,235,108	22.8 percentage of participants
Group 3: rLP2086(0-,6- Month)+Saline(1-,2- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	Before Inj1:PMB2707 1:128;N=363,357,370,241,113	0.3 percentage of participants
Group 3: rLP2086(0-,6- Month)+Saline(1-,2- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	Before Inj1:PMB80[A22] 1:32; N=356,352,364,235,108	13.5 percentage of participants
Group 3: rLP2086(0-,6- Month)+Saline(1-,2- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	Before Inj1:PMB80[A22] 1:64; N=356,352,364,235,108	4.7 percentage of participants
Group 3: rLP2086(0-,6- Month)+Saline(1-,2- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	Before Inj1:PMB80[A22]1:128; N=356,352,364,235,108	1.6 percentage of participants
Group 3: rLP2086(0-,6- Month)+Saline(1-,2- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	1M aft Inj4:PMB2707 1:128;N=356,352,356,230,111	13.8 percentage of participants
Group 3: rLP2086(0-,6- Month)+Saline(1-,2- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	1M aft Inj2:PMB80[A22] 1:4; N=351,345,351,224,110	51.3 percentage of participants
Group 3: rLP2086(0-,6- Month)+Saline(1-,2- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	1M aft Inj2:PMB80[A22] 1:16; N=351,345,351,224,110	50.7 percentage of participants
Group 3: rLP2086(0-,6- Month)+Saline(1-,2- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	1M aft Inj2:PMB2707[B44]1:4;N=341,345,349,225,111	20.6 percentage of participants
Group 3: rLP2086(0-,6- Month)+Saline(1-,2- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	1M aft Inj2:PMB80[A22] 1:32; N=351,345,351,224,110	34.5 percentage of participants
Group 3: rLP2086(0-,6- Month)+Saline(1-,2- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	1M aft Inj2:PMB80[A22] 1:64; N=351,345,351,224,110	14.5 percentage of participants
Group 3: rLP2086(0-,6- Month)+Saline(1-,2- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	1M aft Inj2:PMB80[A22]1:128; N=351,345,351,224,110	5.7 percentage of participants
Group 3: rLP2086(0-,6- Month)+Saline(1-,2- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	1M aft Inj3:PMB80[A22] 1:4; N=332,344,340,238,102	45.6 percentage of participants
Group 3: rLP2086(0-,6- Month)+Saline(1-,2- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	1M aft Inj3:PMB80[A22]1:16; N=332,344,340,238,102	42.4 percentage of participants
Group 3: rLP2086(0-,6- Month)+Saline(1-,2- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	1M aft Inj2:PMB2707[B44]1:16;N=341,345,349,225,111	14.0 percentage of participants
Group 3: rLP2086(0-,6- Month)+Saline(1-,2- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	1M aft Inj3:PMB80[A22]1:32; N=332,344,340,238,102	30.6 percentage of participants
Group 3: rLP2086(0-,6- Month)+Saline(1-,2- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	1M aft Inj3:PMB80[A22]1:64; N=332,344,340,238,102	12.4 percentage of participants
Group 3: rLP2086(0-,6- Month)+Saline(1-,2- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	1M aft Inj3:PMB80[A22]1:128; N=332,344,340,238,102	4.4 percentage of participants
Group 3: rLP2086(0-,6- Month)+Saline(1-,2- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	1M aft Inj4:PMB2707[B44]1:32;N=356,352,356,230,111	49.2 percentage of participants
Group 3: rLP2086(0-,6- Month)+Saline(1-,2- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	1M aft Inj4:PMB80[A22] 1:4; N=360,357,369,234,111	94.0 percentage of participants
Group 4: rLP2086(0-,2- Month)+Saline(1-,6- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	1M aft Inj3:PMB2948[B24]1:32;N=328,337,340,237,102	43.5 percentage of participants
Group 4: rLP2086(0-,2- Month)+Saline(1-,6- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	1M aft Inj4:PMB2948[B24]1:16;N=354,354,359,228,110	32.9 percentage of participants
Group 4: rLP2086(0-,2- Month)+Saline(1-,6- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	1M aft Inj3:PMB2948[B24]1:4;N=328,337,340,237,102	75.5 percentage of participants
Group 4: rLP2086(0-,2- Month)+Saline(1-,6- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	Before Inj1:PMB80[A22] 1:4; N=356,352,364,235,108	23.8 percentage of participants
Group 4: rLP2086(0-,2- Month)+Saline(1-,6- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	1M aft Inj3:PMB2707 1:128;N=333,331,341,234,105	14.1 percentage of participants
Group 4: rLP2086(0-,2- Month)+Saline(1-,6- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	Before Inj1:PMB2001[A56]1:64;N=350,348,355,231,107	8.7 percentage of participants
Group 4: rLP2086(0-,2- Month)+Saline(1-,6- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	1M aft Inj2:PMB2707[B44]1:64;N=341,345,349,225,111	6.2 percentage of participants
Group 4: rLP2086(0-,2- Month)+Saline(1-,6- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	1M aft Inj2:PMB2001[A56]1:32;N=353,329,335,218,102	47.2 percentage of participants
Group 4: rLP2086(0-,2- Month)+Saline(1-,6- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	Before Inj1:PMB80[A22] 1:16; N=356,352,364,235,108	22.1 percentage of participants
Group 4: rLP2086(0-,2- Month)+Saline(1-,6- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	1M aft Inj2:PMB2948 1:128;N=344,345,352,223,110	4.5 percentage of participants
Group 4: rLP2086(0-,2- Month)+Saline(1-,6- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	1M aft Inj4:PMB2948[B24]1:32;N=354,354,359,228,110	18.0 percentage of participants
Group 4: rLP2086(0-,2- Month)+Saline(1-,6- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	1M aft Inj4:PMB80[A22]1:128; N=360,357,369,234,111	8.5 percentage of participants
Group 4: rLP2086(0-,2- Month)+Saline(1-,6- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	1M aft Inj4:PMB80[A22] 1:4; N=360,357,369,234,111	58.1 percentage of participants
Group 4: rLP2086(0-,2- Month)+Saline(1-,6- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	Before Inj1:PMB80[A22] 1:32; N=356,352,364,235,108	13.2 percentage of participants
Group 4: rLP2086(0-,2- Month)+Saline(1-,6- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	1M aft Inj4:PMB2707[B44]1:4;N=356,352,356,230,111	26.1 percentage of participants
Group 4: rLP2086(0-,2- Month)+Saline(1-,6- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	Before Inj1:PMB2707 1:128;N=363,357,370,241,113	0.8 percentage of participants
Group 4: rLP2086(0-,2- Month)+Saline(1-,6- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	Before Inj1:PMB2001[A56]1:32;N=350,348,355,231,107	15.6 percentage of participants
Group 4: rLP2086(0-,2- Month)+Saline(1-,6- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	1M aft Inj3:PMB80[A22]1:32; N=332,344,340,238,102	70.6 percentage of participants
Group 4: rLP2086(0-,2- Month)+Saline(1-,6- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	Before Inj1:PMB80[A22] 1:64; N=356,352,364,235,108	6.8 percentage of participants
Group 4: rLP2086(0-,2- Month)+Saline(1-,6- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	1M aft Inj3:PMB2948[B24]1:64;N=328,337,340,237,102	19.4 percentage of participants
Group 4: rLP2086(0-,2- Month)+Saline(1-,6- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	1M aft Inj4:PMB2707 1:128;N=356,352,356,230,111	3.9 percentage of participants
Group 4: rLP2086(0-,2- Month)+Saline(1-,6- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	1M aft Inj4:PMB2948[B24]1:64;N=354,354,359,228,110	10.5 percentage of participants
Group 4: rLP2086(0-,2- Month)+Saline(1-,6- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	1M aft Inj2:PMB2707[B44]1:4;N=341,345,349,225,111	20.4 percentage of participants
Group 4: rLP2086(0-,2- Month)+Saline(1-,6- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	Before Inj1:PMB80[A22]1:128; N=356,352,364,235,108	2.6 percentage of participants
Group 4: rLP2086(0-,2- Month)+Saline(1-,6- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	1M aft Inj2:PMB80[A22] 1:64; N=351,345,351,224,110	19.6 percentage of participants
Group 4: rLP2086(0-,2- Month)+Saline(1-,6- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	1M aft Inj2:PMB2707[B44]1:16;N=341,345,349,225,111	14.2 percentage of participants
Group 4: rLP2086(0-,2- Month)+Saline(1-,6- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	1M aft Inj2:PMB2001[A56]1:16;N=353,329,335,218,102	55.5 percentage of participants
Group 4: rLP2086(0-,2- Month)+Saline(1-,6- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	Before Inj1:PMB2001[A56]1:16;N=350,348,355,231,107	19.0 percentage of participants
Group 4: rLP2086(0-,2- Month)+Saline(1-,6- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	1M aft Inj4:PMB2001[A56]1:32;N=362,359,370,228,113	59.6 percentage of participants
Group 4: rLP2086(0-,2- Month)+Saline(1-,6- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	1M aft Inj3:PMB80[A22] 1:4; N=332,344,340,238,102	90.8 percentage of participants
Group 4: rLP2086(0-,2- Month)+Saline(1-,6- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	1M aft Inj3:PMB2707[B44]1:16;N=333,331,341,234,105	64.5 percentage of participants
Group 4: rLP2086(0-,2- Month)+Saline(1-,6- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	1M aft Inj4:PMB2001[A56]1:16;N=362,359,370,228,113	74.6 percentage of participants
Group 4: rLP2086(0-,2- Month)+Saline(1-,6- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	1M aft Inj4:PMB80[A22] 1:32; N=360,357,369,234,111	38.0 percentage of participants
Group 4: rLP2086(0-,2- Month)+Saline(1-,6- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	1M aft Inj4:PMB2001[A56]1:64;N=362,359,370,228,113	34.2 percentage of participants
Group 4: rLP2086(0-,2- Month)+Saline(1-,6- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	1M aft Inj4:PMB2948 1:128;N=354,354,359,228,110	3.1 percentage of participants
Group 4: rLP2086(0-,2- Month)+Saline(1-,6- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	1M aft Inj3:PMB2948[B24]1:16;N=328,337,340,237,102	67.1 percentage of participants
Group 4: rLP2086(0-,2- Month)+Saline(1-,6- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	1M aft Inj3:PMB2948 1:128;N=328,337,340,237,102	8.4 percentage of participants
Group 4: rLP2086(0-,2- Month)+Saline(1-,6- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	1M aft Inj2:PMB80[A22] 1:4; N=351,345,351,224,110	52.2 percentage of participants
Group 4: rLP2086(0-,2- Month)+Saline(1-,6- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	1M aft Inj4:PMB2001 1:128;N=362,359,370,228,113	15.8 percentage of participants
Group 4: rLP2086(0-,2- Month)+Saline(1-,6- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	1M aft Inj2:PMB2001[A56] 1:4;N=353,329,335,218,102	60.1 percentage of participants
Group 4: rLP2086(0-,2- Month)+Saline(1-,6- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	1M aft Inj2:PMB2948[B24]1:64;N=344,345,352,223,110	11.7 percentage of participants
Group 4: rLP2086(0-,2- Month)+Saline(1-,6- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	1M aft Inj4:PMB2001[A56] 1:4;N=362,359,370,228,113	79.8 percentage of participants
Group 4: rLP2086(0-,2- Month)+Saline(1-,6- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	Before Inj1:PMB2707[B44]1:4;N=363,357,370,241,113	8.3 percentage of participants
Group 4: rLP2086(0-,2- Month)+Saline(1-,6- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	Before Inj1:PMB2948[B24]1:4;N=362,356,369,241,112	13.3 percentage of participants
Group 4: rLP2086(0-,2- Month)+Saline(1-,6- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	1M aft Inj3:PMB2001[A56] 1:4;N=329,339,320,240,102	100.0 percentage of participants
Group 4: rLP2086(0-,2- Month)+Saline(1-,6- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	1M aft Inj2:PMB2001[A56]1:64;N=353,329,335,218,102	29.8 percentage of participants
Group 4: rLP2086(0-,2- Month)+Saline(1-,6- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	1M aft Inj3:PMB2001 1:128;N=329,339,320,240,102	57.1 percentage of participants
Group 4: rLP2086(0-,2- Month)+Saline(1-,6- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	Before Inj1:PMB2001[A56] 1:4;N=350,348,355,231,107	25.5 percentage of participants
Group 4: rLP2086(0-,2- Month)+Saline(1-,6- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	Before Inj1:PMB2948[B24]1:16;N=362,356,369,241,112	8.7 percentage of participants
Group 4: rLP2086(0-,2- Month)+Saline(1-,6- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	1M aft Inj2:PMB80[A22]1:128; N=351,345,351,224,110	8.5 percentage of participants
Group 4: rLP2086(0-,2- Month)+Saline(1-,6- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	1M aft Inj4:PMB80[A22] 1:16; N=360,357,369,234,111	56.0 percentage of participants
Group 4: rLP2086(0-,2- Month)+Saline(1-,6- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	1M aft Inj4:PMB80[A22] 1:64; N=360,357,369,234,111	19.2 percentage of participants
Group 4: rLP2086(0-,2- Month)+Saline(1-,6- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	1M aft Inj2:PMB80[A22] 1:16; N=351,345,351,224,110	51.8 percentage of participants
Group 4: rLP2086(0-,2- Month)+Saline(1-,6- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	Before Inj1:PMB2948[B24]1:32;N=362,356,369,241,112	5.0 percentage of participants
Group 4: rLP2086(0-,2- Month)+Saline(1-,6- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	Before Inj1:PMB2707[B44]1:16;N=363,357,370,241,113	6.6 percentage of participants
Group 4: rLP2086(0-,2- Month)+Saline(1-,6- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	1M aft Inj3:PMB2707[B44]1:32;N=333,331,341,234,105	42.3 percentage of participants
Group 4: rLP2086(0-,2- Month)+Saline(1-,6- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	1M aft Inj4:PMB2948[B24]1:4;N=354,354,359,228,110	38.2 percentage of participants
Group 4: rLP2086(0-,2- Month)+Saline(1-,6- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	1M aft Inj2:PMB2707[B44]1:32;N=341,345,349,225,111	9.8 percentage of participants
Group 4: rLP2086(0-,2- Month)+Saline(1-,6- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	Before Inj1:PMB2948[B24]1:64;N=362,356,369,241,112	2.1 percentage of participants
Group 4: rLP2086(0-,2- Month)+Saline(1-,6- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	Before Inj1: PMB2001 1:128;N=350,348,355,231,107	2.6 percentage of participants
Group 4: rLP2086(0-,2- Month)+Saline(1-,6- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	1M aft Inj3:PMB80[A22]1:128; N=332,344,340,238,102	19.7 percentage of participants
Group 4: rLP2086(0-,2- Month)+Saline(1-,6- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	1M aft Inj3:PMB2001[A56]1:64;N=329,339,320,240,102	81.7 percentage of participants
Group 4: rLP2086(0-,2- Month)+Saline(1-,6- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	1M aft Inj3:PMB80[A22]1:64; N=332,344,340,238,102	39.1 percentage of participants
Group 4: rLP2086(0-,2- Month)+Saline(1-,6- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	Before Inj1:PMB2948 1:128;N=362,356,369,241,112	0.8 percentage of participants
Group 4: rLP2086(0-,2- Month)+Saline(1-,6- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	Before Inj1:PMB2707[B44]1:32;N=363,357,370,241,113	2.9 percentage of participants
Group 4: rLP2086(0-,2- Month)+Saline(1-,6- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	1M aft Inj4:PMB2707[B44]1:64;N=356,352,356,230,111	5.2 percentage of participants
Group 4: rLP2086(0-,2- Month)+Saline(1-,6- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	1M aft Inj3:PMB2707[B44]1:4;N=333,331,341,234,105	73.5 percentage of participants
Group 4: rLP2086(0-,2- Month)+Saline(1-,6- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	1M aft Inj4:PMB2707[B44]1:32;N=356,352,356,230,111	10.0 percentage of participants
Group 4: rLP2086(0-,2- Month)+Saline(1-,6- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	1M aft Inj2:PMB2948[B24]1:4;N=344,345,352,223,110	47.1 percentage of participants
Group 4: rLP2086(0-,2- Month)+Saline(1-,6- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	1M aft Inj2:PMB2001 1:128;N=353,329,335,218,102	15.6 percentage of participants
Group 4: rLP2086(0-,2- Month)+Saline(1-,6- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	1M aft Inj4:PMB2707[B44]1:16;N=356,352,356,230,111	19.1 percentage of participants
Group 4: rLP2086(0-,2- Month)+Saline(1-,6- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	1M aft Inj3:PMB2001[A56]1:32;N=329,339,320,240,102	95.0 percentage of participants
Group 4: rLP2086(0-,2- Month)+Saline(1-,6- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	1M aft Inj2:PMB2707 1:128;N=341,345,349,225,111	4.0 percentage of participants
Group 4: rLP2086(0-,2- Month)+Saline(1-,6- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	1M aft Inj2:PMB2948[B24]1:16;N=344,345,352,223,110	40.4 percentage of participants
Group 4: rLP2086(0-,2- Month)+Saline(1-,6- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	1M aft Inj3:PMB80[A22]1:16; N=332,344,340,238,102	90.8 percentage of participants
Group 4: rLP2086(0-,2- Month)+Saline(1-,6- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	1M aft Inj2:PMB80[A22] 1:32; N=351,345,351,224,110	37.9 percentage of participants
Group 4: rLP2086(0-,2- Month)+Saline(1-,6- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	Before Inj1:PMB2707[B44]1:64;N=363,357,370,241,113	1.2 percentage of participants
Group 4: rLP2086(0-,2- Month)+Saline(1-,6- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	1M aft Inj3:PMB2001[A56]1:16;N=329,339,320,240,102	99.2 percentage of participants
Group 4: rLP2086(0-,2- Month)+Saline(1-,6- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	1M aft Inj2:PMB2948[B24]1:32;N=344,345,352,223,110	24.7 percentage of participants
Group 4: rLP2086(0-,2- Month)+Saline(1-,6- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	1M aft Inj3:PMB2707[B44]1:64;N=333,331,341,234,105	24.4 percentage of participants
Group 5: rLP2086(2-,6- Month)+ Saline(0-,1- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	1M aft Inj2:PMB2948[B24]1:32;N=344,345,352,223,110	5.5 percentage of participants
Group 5: rLP2086(2-,6- Month)+ Saline(0-,1- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	1M aft Inj2:PMB2948[B24]1:64;N=344,345,352,223,110	3.6 percentage of participants
Group 5: rLP2086(2-,6- Month)+ Saline(0-,1- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	1M aft Inj3:PMB2707[B44]1:64;N=333,331,341,234,105	7.6 percentage of participants
Group 5: rLP2086(2-,6- Month)+ Saline(0-,1- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	1M aft Inj3:PMB2001[A56] 1:4;N=329,339,320,240,102	72.5 percentage of participants
Group 5: rLP2086(2-,6- Month)+ Saline(0-,1- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	1M aft Inj4:PMB80[A22]1:128; N=360,357,369,234,111	20.7 percentage of participants
Group 5: rLP2086(2-,6- Month)+ Saline(0-,1- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	1M aft Inj2:PMB2948 1:128;N=344,345,352,223,110	0.0 percentage of participants
Group 5: rLP2086(2-,6- Month)+ Saline(0-,1- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	1M aft Inj4:PMB2707[B44]1:64;N=356,352,356,230,111	20.7 percentage of participants
Group 5: rLP2086(2-,6- Month)+ Saline(0-,1- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	1M aft Inj2:PMB2707[B44]1:16;N=341,345,349,225,111	4.5 percentage of participants
Group 5: rLP2086(2-,6- Month)+ Saline(0-,1- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	1M aft Inj3:PMB2948[B24]1:4;N=328,337,340,237,102	57.8 percentage of participants
Group 5: rLP2086(2-,6- Month)+ Saline(0-,1- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	1M aft Inj2:PMB2001 1:128;N=353,329,335,218,102	2.9 percentage of participants
Group 5: rLP2086(2-,6- Month)+ Saline(0-,1- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	1M aft Inj3:PMB2948[B24]1:16;N=328,337,340,237,102	52.9 percentage of participants
Group 5: rLP2086(2-,6- Month)+ Saline(0-,1- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	1M aft Inj2:PMB80[A22] 1:64; N=351,345,351,224,110	6.4 percentage of participants
Group 5: rLP2086(2-,6- Month)+ Saline(0-,1- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	1M aft Inj2:PMB2707[B44]1:4;N=341,345,349,225,111	5.4 percentage of participants
Group 5: rLP2086(2-,6- Month)+ Saline(0-,1- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	1M aft Inj3:PMB2948[B24]1:32;N=328,337,340,237,102	32.4 percentage of participants
Group 5: rLP2086(2-,6- Month)+ Saline(0-,1- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	1M aft Inj2:PMB2707 1:128;N=341,345,349,225,111	0.0 percentage of participants
Group 5: rLP2086(2-,6- Month)+ Saline(0-,1- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	1M aft Inj3:PMB2948[B24]1:64;N=328,337,340,237,102	15.7 percentage of participants
Group 5: rLP2086(2-,6- Month)+ Saline(0-,1- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	1M aft Inj3:PMB2707 1:128;N=333,331,341,234,105	3.8 percentage of participants
Group 5: rLP2086(2-,6- Month)+ Saline(0-,1- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	1M aft Inj2:PMB2001[A56]1:64;N=353,329,335,218,102	10.8 percentage of participants
Group 5: rLP2086(2-,6- Month)+ Saline(0-,1- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	1M aft Inj4:PMB80[A22] 1:16; N=360,357,369,234,111	91.0 percentage of participants
Group 5: rLP2086(2-,6- Month)+ Saline(0-,1- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	1M aft Inj3:PMB2948 1:128;N=328,337,340,237,102	6.9 percentage of participants
Group 5: rLP2086(2-,6- Month)+ Saline(0-,1- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	1M aft Inj4:PMB2707 1:128;N=356,352,356,230,111	9.0 percentage of participants
Group 5: rLP2086(2-,6- Month)+ Saline(0-,1- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	1M aft Inj4:PMB2948[B24]1:4;N=354,354,359,228,110	70.9 percentage of participants
Group 5: rLP2086(2-,6- Month)+ Saline(0-,1- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	1M aft Inj2:PMB2001[A56]1:32;N=353,329,335,218,102	17.6 percentage of participants
Group 5: rLP2086(2-,6- Month)+ Saline(0-,1- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	1M aft Inj2:PMB80[A22]1:128; N=351,345,351,224,110	0.9 percentage of participants
Group 5: rLP2086(2-,6- Month)+ Saline(0-,1- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	1M aft Inj4:PMB2948[B24]1:16;N=354,354,359,228,110	64.5 percentage of participants
Group 5: rLP2086(2-,6- Month)+ Saline(0-,1- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	1M aft Inj2:PMB2707[B44]1:32;N=341,345,349,225,111	3.6 percentage of participants
Group 5: rLP2086(2-,6- Month)+ Saline(0-,1- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	1M aft Inj4:PMB80[A22] 1:64; N=360,357,369,234,111	42.3 percentage of participants
Group 5: rLP2086(2-,6- Month)+ Saline(0-,1- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	1M aft Inj4:PMB2948[B24]1:32;N=354,354,359,228,110	33.6 percentage of participants
Group 5: rLP2086(2-,6- Month)+ Saline(0-,1- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	1M aft Inj2:PMB2001[A56]1:16;N=353,329,335,218,102	21.6 percentage of participants
Group 5: rLP2086(2-,6- Month)+ Saline(0-,1- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	1M aft Inj4:PMB80[A22] 1:4; N=360,357,369,234,111	91.9 percentage of participants
Group 5: rLP2086(2-,6- Month)+ Saline(0-,1- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	1M aft Inj4:PMB2948[B24]1:64;N=354,354,359,228,110	12.7 percentage of participants
Group 5: rLP2086(2-,6- Month)+ Saline(0-,1- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	1M aft Inj4:PMB2707[B44]1:4;N=356,352,356,230,111	73.0 percentage of participants
Group 5: rLP2086(2-,6- Month)+ Saline(0-,1- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	1M aft Inj4:PMB2948 1:128;N=354,354,359,228,110	6.4 percentage of participants
Group 5: rLP2086(2-,6- Month)+ Saline(0-,1- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	1M aft Inj2:PMB2001[A56] 1:4;N=353,329,335,218,102	25.5 percentage of participants
Group 5: rLP2086(2-,6- Month)+ Saline(0-,1- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	1M aft Inj3:PMB80[A22] 1:4; N=332,344,340,238,102	55.9 percentage of participants
Group 5: rLP2086(2-,6- Month)+ Saline(0-,1- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	Before Inj1:PMB2707[B44]1:4;N=363,357,370,241,113	7.1 percentage of participants
Group 5: rLP2086(2-,6- Month)+ Saline(0-,1- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	1M aft Inj4:PMB2707[B44]1:32;N=356,352,356,230,111	39.6 percentage of participants
Group 5: rLP2086(2-,6- Month)+ Saline(0-,1- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	Before Inj1: PMB2001 1:128;N=350,348,355,231,107	2.8 percentage of participants
Group 5: rLP2086(2-,6- Month)+ Saline(0-,1- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	Before Inj1:PMB2707[B44]1:16;N=363,357,370,241,113	4.4 percentage of participants
Group 5: rLP2086(2-,6- Month)+ Saline(0-,1- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	Before Inj1:PMB2707[B44]1:32;N=363,357,370,241,113	3.5 percentage of participants
Group 5: rLP2086(2-,6- Month)+ Saline(0-,1- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	1M aft Inj2:PMB2707[B44]1:64;N=341,345,349,225,111	0.9 percentage of participants
Group 5: rLP2086(2-,6- Month)+ Saline(0-,1- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	Before Inj1:PMB2707[B44]1:64;N=363,357,370,241,113	0.9 percentage of participants
Group 5: rLP2086(2-,6- Month)+ Saline(0-,1- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	1M aft Inj4:PMB2707[B44]1:16;N=356,352,356,230,111	66.7 percentage of participants
Group 5: rLP2086(2-,6- Month)+ Saline(0-,1- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	Before Inj1:PMB2001[A56]1:64;N=350,348,355,231,107	8.4 percentage of participants
Group 5: rLP2086(2-,6- Month)+ Saline(0-,1- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	1M aft Inj3:PMB80[A22]1:16; N=332,344,340,238,102	55.9 percentage of participants
Group 5: rLP2086(2-,6- Month)+ Saline(0-,1- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	Before Inj1:PMB80[A22] 1:4; N=356,352,364,235,108	25.9 percentage of participants
Group 5: rLP2086(2-,6- Month)+ Saline(0-,1- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	1M aft Inj3:PMB80[A22]1:128; N=332,344,340,238,102	14.7 percentage of participants
Group 5: rLP2086(2-,6- Month)+ Saline(0-,1- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	Before Inj1:PMB80[A22] 1:16; N=356,352,364,235,108	24.1 percentage of participants
Group 5: rLP2086(2-,6- Month)+ Saline(0-,1- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	1M aft Inj4:PMB80[A22] 1:32; N=360,357,369,234,111	74.8 percentage of participants
Group 5: rLP2086(2-,6- Month)+ Saline(0-,1- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	Before Inj1:PMB2001[A56]1:32;N=350,348,355,231,107	15.9 percentage of participants
Group 5: rLP2086(2-,6- Month)+ Saline(0-,1- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	Before Inj1:PMB80[A22] 1:32; N=356,352,364,235,108	15.7 percentage of participants
Group 5: rLP2086(2-,6- Month)+ Saline(0-,1- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	Before Inj1:PMB80[A22] 1:64; N=356,352,364,235,108	7.4 percentage of participants
Group 5: rLP2086(2-,6- Month)+ Saline(0-,1- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	Before Inj1:PMB2707 1:128;N=363,357,370,241,113	0.0 percentage of participants
Group 5: rLP2086(2-,6- Month)+ Saline(0-,1- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	Before Inj1:PMB2001[A56]1:16;N=350,348,355,231,107	16.8 percentage of participants
Group 5: rLP2086(2-,6- Month)+ Saline(0-,1- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	1M aft Inj3:PMB80[A22]1:32; N=332,344,340,238,102	45.1 percentage of participants
Group 5: rLP2086(2-,6- Month)+ Saline(0-,1- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	Before Inj1:PMB80[A22]1:128; N=356,352,364,235,108	1.9 percentage of participants
Group 5: rLP2086(2-,6- Month)+ Saline(0-,1- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	1M aft Inj4:PMB2001[A56]1:16;N=362,359,370,228,113	99.1 percentage of participants
Group 5: rLP2086(2-,6- Month)+ Saline(0-,1- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	1M aft Inj4:PMB2001[A56]1:32;N=362,359,370,228,113	92.9 percentage of participants
Group 5: rLP2086(2-,6- Month)+ Saline(0-,1- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	1M aft Inj4:PMB2001[A56]1:64;N=362,359,370,228,113	85.0 percentage of participants
Group 5: rLP2086(2-,6- Month)+ Saline(0-,1- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	1M aft Inj3:PMB2707[B44]1:16;N=333,331,341,234,105	21.0 percentage of participants
Group 5: rLP2086(2-,6- Month)+ Saline(0-,1- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	1M aft Inj4:PMB2001[A56] 1:4;N=362,359,370,228,113	99.1 percentage of participants
Group 5: rLP2086(2-,6- Month)+ Saline(0-,1- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	1M aft Inj4:PMB2001 1:128;N=362,359,370,228,113	60.2 percentage of participants
Group 5: rLP2086(2-,6- Month)+ Saline(0-,1- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	1M aft Inj2:PMB80[A22] 1:4; N=351,345,351,224,110	29.1 percentage of participants
Group 5: rLP2086(2-,6- Month)+ Saline(0-,1- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	Before Inj1:PMB2001[A56] 1:4;N=350,348,355,231,107	25.2 percentage of participants
Group 5: rLP2086(2-,6- Month)+ Saline(0-,1- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	Before Inj1:PMB2948[B24]1:4;N=362,356,369,241,112	16.1 percentage of participants
Group 5: rLP2086(2-,6- Month)+ Saline(0-,1- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	1M aft Inj3:PMB2001 1:128;N=329,339,320,240,102	22.5 percentage of participants
Group 5: rLP2086(2-,6- Month)+ Saline(0-,1- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	Before Inj1:PMB2948[B24]1:16;N=362,356,369,241,112	12.5 percentage of participants
Group 5: rLP2086(2-,6- Month)+ Saline(0-,1- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	1M aft Inj3:PMB2707[B44]1:4;N=333,331,341,234,105	28.6 percentage of participants
Group 5: rLP2086(2-,6- Month)+ Saline(0-,1- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	Before Inj1:PMB2948[B24]1:32;N=362,356,369,241,112	4.5 percentage of participants
Group 5: rLP2086(2-,6- Month)+ Saline(0-,1- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	1M aft Inj3:PMB2001[A56]1:64;N=329,339,320,240,102	39.2 percentage of participants
Group 5: rLP2086(2-,6- Month)+ Saline(0-,1- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	1M aft Inj2:PMB80[A22] 1:16; N=351,345,351,224,110	27.3 percentage of participants
Group 5: rLP2086(2-,6- Month)+ Saline(0-,1- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	Before Inj1:PMB2948[B24]1:64;N=362,356,369,241,112	2.7 percentage of participants
Group 5: rLP2086(2-,6- Month)+ Saline(0-,1- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	1M aft Inj3:PMB2707[B44]1:32;N=333,331,341,234,105	13.3 percentage of participants
Group 5: rLP2086(2-,6- Month)+ Saline(0-,1- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	Before Inj1:PMB2948 1:128;N=362,356,369,241,112	1.8 percentage of participants
Group 5: rLP2086(2-,6- Month)+ Saline(0-,1- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	1M aft Inj2:PMB2948[B24]1:4;N=344,345,352,223,110	20.0 percentage of participants
Group 5: rLP2086(2-,6- Month)+ Saline(0-,1- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	1M aft Inj3:PMB2001[A56]1:32;N=329,339,320,240,102	55.9 percentage of participants
Group 5: rLP2086(2-,6- Month)+ Saline(0-,1- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	1M aft Inj3:PMB80[A22]1:64; N=332,344,340,238,102	22.5 percentage of participants
Group 5: rLP2086(2-,6- Month)+ Saline(0-,1- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	1M aft Inj2:PMB2948[B24]1:16;N=344,345,352,223,110	14.5 percentage of participants
Group 5: rLP2086(2-,6- Month)+ Saline(0-,1- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	1M aft Inj3:PMB2001[A56]1:16;N=329,339,320,240,102	65.7 percentage of participants
Group 5: rLP2086(2-,6- Month)+ Saline(0-,1- Month)	Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level	1M aft Inj2:PMB80[A22] 1:32; N=351,345,351,224,110	18.2 percentage of participants

Secondary

Serum Bactericidal Assay Using Human Complement (hSBA) Geometric Mean Titers (GMTs)

Time frame: Before Injection (Inj) 1, 1 Month (M) after (aft) Injection 2, 3, 4

Population: The number of participants shown for each test strain represents the number with valid and determinant assay result for that strain.

Arm	Measure	Group	Value (GEOMETRIC_MEAN)
Group 1:rLP2086(0-,1-,6- Month)+Saline(2- Month)	Serum Bactericidal Assay Using Human Complement (hSBA) Geometric Mean Titers (GMTs)	Before Inj1: PMB2001 [A56]; N=350,348,355,231,107	6.8 titer
Group 1:rLP2086(0-,1-,6- Month)+Saline(2- Month)	Serum Bactericidal Assay Using Human Complement (hSBA) Geometric Mean Titers (GMTs)	1M aft Inj2: PMB80 [A22]; N=351,345,351,224,110	24.4 titer
Group 1:rLP2086(0-,1-,6- Month)+Saline(2- Month)	Serum Bactericidal Assay Using Human Complement (hSBA) Geometric Mean Titers (GMTs)	1M aft Inj3: PMB80 [A22]; N=332,344,340,238,102	17.7 titer
Group 1:rLP2086(0-,1-,6- Month)+Saline(2- Month)	Serum Bactericidal Assay Using Human Complement (hSBA) Geometric Mean Titers (GMTs)	1M aft Inj4: PMB80 [A22]; N=360,357,369,234,111	55.1 titer
Group 1:rLP2086(0-,1-,6- Month)+Saline(2- Month)	Serum Bactericidal Assay Using Human Complement (hSBA) Geometric Mean Titers (GMTs)	Before Inj1: PMB80 [A22]; N=356,352,364,235,108	7.1 titer
Group 1:rLP2086(0-,1-,6- Month)+Saline(2- Month)	Serum Bactericidal Assay Using Human Complement (hSBA) Geometric Mean Titers (GMTs)	1M aft Inj2: PMB2001 [A56]; N=353,329,335,218,102	77.3 titer
Group 1:rLP2086(0-,1-,6- Month)+Saline(2- Month)	Serum Bactericidal Assay Using Human Complement (hSBA) Geometric Mean Titers (GMTs)	1M aft Inj3: PMB2001 [A56]; N=329,339,320,240,102	48.3 titer
Group 1:rLP2086(0-,1-,6- Month)+Saline(2- Month)	Serum Bactericidal Assay Using Human Complement (hSBA) Geometric Mean Titers (GMTs)	1M aft Inj4: PMB2001 [A56]; N=362,359,370,228,113	152.9 titer
Group 1:rLP2086(0-,1-,6- Month)+Saline(2- Month)	Serum Bactericidal Assay Using Human Complement (hSBA) Geometric Mean Titers (GMTs)	Before Inj1: PMB2948 [B24]; N=362,356,369,241,112	5.3 titer
Group 1:rLP2086(0-,1-,6- Month)+Saline(2- Month)	Serum Bactericidal Assay Using Human Complement (hSBA) Geometric Mean Titers (GMTs)	1M aft Inj2: PMB2948 [B24]; N=344,345,352,223,110	13.8 titer
Group 1:rLP2086(0-,1-,6- Month)+Saline(2- Month)	Serum Bactericidal Assay Using Human Complement (hSBA) Geometric Mean Titers (GMTs)	1M aft Inj3: PMB2948 [B24]; N=328,337,340,237,102	11.0 titer
Group 1:rLP2086(0-,1-,6- Month)+Saline(2- Month)	Serum Bactericidal Assay Using Human Complement (hSBA) Geometric Mean Titers (GMTs)	1M aft Inj4: PMB2948 [B24]; N=354,354,359,228,110	29.1 titer
Group 1:rLP2086(0-,1-,6- Month)+Saline(2- Month)	Serum Bactericidal Assay Using Human Complement (hSBA) Geometric Mean Titers (GMTs)	Before Inj1: PMB2707 [B44]; N=363,357,370,241,113	4.4 titer
Group 1:rLP2086(0-,1-,6- Month)+Saline(2- Month)	Serum Bactericidal Assay Using Human Complement (hSBA) Geometric Mean Titers (GMTs)	1M aft Inj2: PMB2707 [B44]; N=341,345,349,225,111	13.1 titer
Group 1:rLP2086(0-,1-,6- Month)+Saline(2- Month)	Serum Bactericidal Assay Using Human Complement (hSBA) Geometric Mean Titers (GMTs)	1M aft Inj3: PMB2707 [B44]; N=333,331,341,234,105	8.4 titer
Group 1:rLP2086(0-,1-,6- Month)+Saline(2- Month)	Serum Bactericidal Assay Using Human Complement (hSBA) Geometric Mean Titers (GMTs)	1M aft Inj4: PMB2707 [B44]; N=356,352,356,230,111	40.3 titer
Group 2:rLP2086(0-,2-,6- Month)+Saline(1- Month)	Serum Bactericidal Assay Using Human Complement (hSBA) Geometric Mean Titers (GMTs)	1M aft Inj2: PMB2707 [B44]; N=341,345,349,225,111	5.5 titer
Group 2:rLP2086(0-,2-,6- Month)+Saline(1- Month)	Serum Bactericidal Assay Using Human Complement (hSBA) Geometric Mean Titers (GMTs)	1M aft Inj2: PMB2948 [B24]; N=344,345,352,223,110	8.2 titer
Group 2:rLP2086(0-,2-,6- Month)+Saline(1- Month)	Serum Bactericidal Assay Using Human Complement (hSBA) Geometric Mean Titers (GMTs)	Before Inj1: PMB2948 [B24]; N=362,356,369,241,112	5.1 titer
Group 2:rLP2086(0-,2-,6- Month)+Saline(1- Month)	Serum Bactericidal Assay Using Human Complement (hSBA) Geometric Mean Titers (GMTs)	1M aft Inj3: PMB2707 [B44]; N=333,331,341,234,105	15.5 titer
Group 2:rLP2086(0-,2-,6- Month)+Saline(1- Month)	Serum Bactericidal Assay Using Human Complement (hSBA) Geometric Mean Titers (GMTs)	1M aft Inj4: PMB2001 [A56]; N=362,359,370,228,113	155.6 titer
Group 2:rLP2086(0-,2-,6- Month)+Saline(1- Month)	Serum Bactericidal Assay Using Human Complement (hSBA) Geometric Mean Titers (GMTs)	Before Inj1: PMB2001 [A56]; N=350,348,355,231,107	6.1 titer
Group 2:rLP2086(0-,2-,6- Month)+Saline(1- Month)	Serum Bactericidal Assay Using Human Complement (hSBA) Geometric Mean Titers (GMTs)	1M aft Inj4: PMB80 [A22]; N=360,357,369,234,111	56.3 titer
Group 2:rLP2086(0-,2-,6- Month)+Saline(1- Month)	Serum Bactericidal Assay Using Human Complement (hSBA) Geometric Mean Titers (GMTs)	1M aft Inj2: PMB80 [A22]; N=351,345,351,224,110	10.7 titer
Group 2:rLP2086(0-,2-,6- Month)+Saline(1- Month)	Serum Bactericidal Assay Using Human Complement (hSBA) Geometric Mean Titers (GMTs)	Before Inj1: PMB80 [A22]; N=356,352,364,235,108	6.3 titer
Group 2:rLP2086(0-,2-,6- Month)+Saline(1- Month)	Serum Bactericidal Assay Using Human Complement (hSBA) Geometric Mean Titers (GMTs)	Before Inj1: PMB2707 [B44]; N=363,357,370,241,113	4.5 titer
Group 2:rLP2086(0-,2-,6- Month)+Saline(1- Month)	Serum Bactericidal Assay Using Human Complement (hSBA) Geometric Mean Titers (GMTs)	1M aft Inj2: PMB2001 [A56]; N=353,329,335,218,102	17.0 titer
Group 2:rLP2086(0-,2-,6- Month)+Saline(1- Month)	Serum Bactericidal Assay Using Human Complement (hSBA) Geometric Mean Titers (GMTs)	1M aft Inj3: PMB80 [A22]; N=332,344,340,238,102	32.9 titer
Group 2:rLP2086(0-,2-,6- Month)+Saline(1- Month)	Serum Bactericidal Assay Using Human Complement (hSBA) Geometric Mean Titers (GMTs)	1M aft Inj4: PMB2707 [B44]; N=356,352,356,230,111	35.0 titer
Group 2:rLP2086(0-,2-,6- Month)+Saline(1- Month)	Serum Bactericidal Assay Using Human Complement (hSBA) Geometric Mean Titers (GMTs)	1M aft Inj4: PMB2948 [B24]; N=354,354,359,228,110	25.6 titer
Group 2:rLP2086(0-,2-,6- Month)+Saline(1- Month)	Serum Bactericidal Assay Using Human Complement (hSBA) Geometric Mean Titers (GMTs)	1M aft Inj3: PMB2948 [B24]; N=328,337,340,237,102	14.9 titer
Group 2:rLP2086(0-,2-,6- Month)+Saline(1- Month)	Serum Bactericidal Assay Using Human Complement (hSBA) Geometric Mean Titers (GMTs)	1M aft Inj3: PMB2001 [A56]; N=329,339,320,240,102	94.6 titer
Group 3: rLP2086(0-,6- Month)+Saline(1-,2- Month)	Serum Bactericidal Assay Using Human Complement (hSBA) Geometric Mean Titers (GMTs)	1M aft Inj2: PMB2707 [B44]; N=341,345,349,225,111	5.7 titer
Group 3: rLP2086(0-,6- Month)+Saline(1-,2- Month)	Serum Bactericidal Assay Using Human Complement (hSBA) Geometric Mean Titers (GMTs)	1M aft Inj4: PMB80 [A22]; N=360,357,369,234,111	48.4 titer
Group 3: rLP2086(0-,6- Month)+Saline(1-,2- Month)	Serum Bactericidal Assay Using Human Complement (hSBA) Geometric Mean Titers (GMTs)	Before Inj1: PMB2001 [A56]; N=350,348,355,231,107	6.7 titer
Group 3: rLP2086(0-,6- Month)+Saline(1-,2- Month)	Serum Bactericidal Assay Using Human Complement (hSBA) Geometric Mean Titers (GMTs)	1M aft Inj2: PMB2001 [A56]; N=353,329,335,218,102	18.5 titer
Group 3: rLP2086(0-,6- Month)+Saline(1-,2- Month)	Serum Bactericidal Assay Using Human Complement (hSBA) Geometric Mean Titers (GMTs)	1M aft Inj3: PMB2001 [A56]; N=329,339,320,240,102	15.1 titer
Group 3: rLP2086(0-,6- Month)+Saline(1-,2- Month)	Serum Bactericidal Assay Using Human Complement (hSBA) Geometric Mean Titers (GMTs)	1M aft Inj4: PMB2001 [A56]; N=362,359,370,228,113	125.6 titer
Group 3: rLP2086(0-,6- Month)+Saline(1-,2- Month)	Serum Bactericidal Assay Using Human Complement (hSBA) Geometric Mean Titers (GMTs)	1M aft Inj3: PMB2707 [B44]; N=333,331,341,234,105	5.2 titer
Group 3: rLP2086(0-,6- Month)+Saline(1-,2- Month)	Serum Bactericidal Assay Using Human Complement (hSBA) Geometric Mean Titers (GMTs)	Before Inj1: PMB2948 [B24]; N=362,356,369,241,112	5.0 titer
Group 3: rLP2086(0-,6- Month)+Saline(1-,2- Month)	Serum Bactericidal Assay Using Human Complement (hSBA) Geometric Mean Titers (GMTs)	1M aft Inj2: PMB2948 [B24]; N=344,345,352,223,110	9.2 titer
Group 3: rLP2086(0-,6- Month)+Saline(1-,2- Month)	Serum Bactericidal Assay Using Human Complement (hSBA) Geometric Mean Titers (GMTs)	1M aft Inj3: PMB2948 [B24]; N=328,337,340,237,102	7.5 titer
Group 3: rLP2086(0-,6- Month)+Saline(1-,2- Month)	Serum Bactericidal Assay Using Human Complement (hSBA) Geometric Mean Titers (GMTs)	1M aft Inj4: PMB2948 [B24]; N=354,354,359,228,110	20.6 titer
Group 3: rLP2086(0-,6- Month)+Saline(1-,2- Month)	Serum Bactericidal Assay Using Human Complement (hSBA) Geometric Mean Titers (GMTs)	Before Inj1: PMB2707 [B44]; N=363,357,370,241,113	4.5 titer
Group 3: rLP2086(0-,6- Month)+Saline(1-,2- Month)	Serum Bactericidal Assay Using Human Complement (hSBA) Geometric Mean Titers (GMTs)	Before Inj1: PMB80 [A22]; N=356,352,364,235,108	6.4 titer
Group 3: rLP2086(0-,6- Month)+Saline(1-,2- Month)	Serum Bactericidal Assay Using Human Complement (hSBA) Geometric Mean Titers (GMTs)	1M aft Inj4: PMB2707 [B44]; N=356,352,356,230,111	22.5 titer
Group 3: rLP2086(0-,6- Month)+Saline(1-,2- Month)	Serum Bactericidal Assay Using Human Complement (hSBA) Geometric Mean Titers (GMTs)	1M aft Inj2: PMB80 [A22]; N=351,345,351,224,110	12.0 titer
Group 3: rLP2086(0-,6- Month)+Saline(1-,2- Month)	Serum Bactericidal Assay Using Human Complement (hSBA) Geometric Mean Titers (GMTs)	1M aft Inj3: PMB80 [A22]; N=332,344,340,238,102	10.3 titer
Group 4: rLP2086(0-,2- Month)+Saline(1-,6- Month)	Serum Bactericidal Assay Using Human Complement (hSBA) Geometric Mean Titers (GMTs)	1M aft Inj2: PMB2948 [B24]; N=344,345,352,223,110	9.8 titer
Group 4: rLP2086(0-,2- Month)+Saline(1-,6- Month)	Serum Bactericidal Assay Using Human Complement (hSBA) Geometric Mean Titers (GMTs)	1M aft Inj4: PMB2707 [B44]; N=356,352,356,230,111	6.2 titer
Group 4: rLP2086(0-,2- Month)+Saline(1-,6- Month)	Serum Bactericidal Assay Using Human Complement (hSBA) Geometric Mean Titers (GMTs)	1M aft Inj3: PMB2948 [B24]; N=328,337,340,237,102	17.7 titer
Group 4: rLP2086(0-,2- Month)+Saline(1-,6- Month)	Serum Bactericidal Assay Using Human Complement (hSBA) Geometric Mean Titers (GMTs)	1M aft Inj2: PMB2707 [B44]; N=341,345,349,225,111	5.9 titer
Group 4: rLP2086(0-,2- Month)+Saline(1-,6- Month)	Serum Bactericidal Assay Using Human Complement (hSBA) Geometric Mean Titers (GMTs)	1M aft Inj4: PMB2948 [B24]; N=354,354,359,228,110	8.0 titer
Group 4: rLP2086(0-,2- Month)+Saline(1-,6- Month)	Serum Bactericidal Assay Using Human Complement (hSBA) Geometric Mean Titers (GMTs)	1M aft Inj2: PMB2001 [A56]; N=353,329,335,218,102	17.7 titer
Group 4: rLP2086(0-,2- Month)+Saline(1-,6- Month)	Serum Bactericidal Assay Using Human Complement (hSBA) Geometric Mean Titers (GMTs)	Before Inj1: PMB2707 [B44]; N=363,357,370,241,113	4.6 titer
Group 4: rLP2086(0-,2- Month)+Saline(1-,6- Month)	Serum Bactericidal Assay Using Human Complement (hSBA) Geometric Mean Titers (GMTs)	1M aft Inj4: PMB80 [A22]; N=360,357,369,234,111	14.2 titer
Group 4: rLP2086(0-,2- Month)+Saline(1-,6- Month)	Serum Bactericidal Assay Using Human Complement (hSBA) Geometric Mean Titers (GMTs)	Before Inj1: PMB80 [A22]; N=356,352,364,235,108	6.4 titer
Group 4: rLP2086(0-,2- Month)+Saline(1-,6- Month)	Serum Bactericidal Assay Using Human Complement (hSBA) Geometric Mean Titers (GMTs)	1M aft Inj3: PMB80 [A22]; N=332,344,340,238,102	37.1 titer
Group 4: rLP2086(0-,2- Month)+Saline(1-,6- Month)	Serum Bactericidal Assay Using Human Complement (hSBA) Geometric Mean Titers (GMTs)	1M aft Inj4: PMB2001 [A56]; N=362,359,370,228,113	26.5 titer
Group 4: rLP2086(0-,2- Month)+Saline(1-,6- Month)	Serum Bactericidal Assay Using Human Complement (hSBA) Geometric Mean Titers (GMTs)	Before Inj1: PMB2001 [A56]; N=350,348,355,231,107	6.3 titer
Group 4: rLP2086(0-,2- Month)+Saline(1-,6- Month)	Serum Bactericidal Assay Using Human Complement (hSBA) Geometric Mean Titers (GMTs)	Before Inj1: PMB2948 [B24]; N=362,356,369,241,112	4.9 titer
Group 4: rLP2086(0-,2- Month)+Saline(1-,6- Month)	Serum Bactericidal Assay Using Human Complement (hSBA) Geometric Mean Titers (GMTs)	1M aft Inj3: PMB2707 [B44]; N=333,331,341,234,105	19.1 titer
Group 4: rLP2086(0-,2- Month)+Saline(1-,6- Month)	Serum Bactericidal Assay Using Human Complement (hSBA) Geometric Mean Titers (GMTs)	1M aft Inj3: PMB2001 [A56]; N=329,339,320,240,102	104.9 titer
Group 4: rLP2086(0-,2- Month)+Saline(1-,6- Month)	Serum Bactericidal Assay Using Human Complement (hSBA) Geometric Mean Titers (GMTs)	1M aft Inj2: PMB80 [A22]; N=351,345,351,224,110	13.3 titer
Group 5: rLP2086(2-,6- Month)+ Saline(0-,1- Month)	Serum Bactericidal Assay Using Human Complement (hSBA) Geometric Mean Titers (GMTs)	Before Inj1: PMB2707 [B44]; N=363,357,370,241,113	4.4 titer
Group 5: rLP2086(2-,6- Month)+ Saline(0-,1- Month)	Serum Bactericidal Assay Using Human Complement (hSBA) Geometric Mean Titers (GMTs)	1M aft Inj2: PMB2948 [B24]; N=344,345,352,223,110	5.3 titer
Group 5: rLP2086(2-,6- Month)+ Saline(0-,1- Month)	Serum Bactericidal Assay Using Human Complement (hSBA) Geometric Mean Titers (GMTs)	1M aft Inj3: PMB2707 [B44]; N=333,331,341,234,105	6.8 titer
Group 5: rLP2086(2-,6- Month)+ Saline(0-,1- Month)	Serum Bactericidal Assay Using Human Complement (hSBA) Geometric Mean Titers (GMTs)	Before Inj1: PMB2001 [A56]; N=350,348,355,231,107	6.2 titer
Group 5: rLP2086(2-,6- Month)+ Saline(0-,1- Month)	Serum Bactericidal Assay Using Human Complement (hSBA) Geometric Mean Titers (GMTs)	1M aft Inj2: PMB80 [A22]; N=351,345,351,224,110	7.1 titer
Group 5: rLP2086(2-,6- Month)+ Saline(0-,1- Month)	Serum Bactericidal Assay Using Human Complement (hSBA) Geometric Mean Titers (GMTs)	1M aft Inj4: PMB2001 [A56]; N=362,359,370,228,113	111.8 titer
Group 5: rLP2086(2-,6- Month)+ Saline(0-,1- Month)	Serum Bactericidal Assay Using Human Complement (hSBA) Geometric Mean Titers (GMTs)	1M aft Inj3: PMB2948 [B24]; N=328,337,340,237,102	12.6 titer
Group 5: rLP2086(2-,6- Month)+ Saline(0-,1- Month)	Serum Bactericidal Assay Using Human Complement (hSBA) Geometric Mean Titers (GMTs)	1M aft Inj4: PMB2707 [B44]; N=356,352,356,230,111	17.8 titer
Group 5: rLP2086(2-,6- Month)+ Saline(0-,1- Month)	Serum Bactericidal Assay Using Human Complement (hSBA) Geometric Mean Titers (GMTs)	1M aft Inj2: PMB2001 [A56]; N=353,329,335,218,102	6.8 titer
Group 5: rLP2086(2-,6- Month)+ Saline(0-,1- Month)	Serum Bactericidal Assay Using Human Complement (hSBA) Geometric Mean Titers (GMTs)	Before Inj1: PMB2948 [B24]; N=362,356,369,241,112	5.1 titer
Group 5: rLP2086(2-,6- Month)+ Saline(0-,1- Month)	Serum Bactericidal Assay Using Human Complement (hSBA) Geometric Mean Titers (GMTs)	Before Inj1: PMB80 [A22]; N=356,352,364,235,108	6.8 titer
Group 5: rLP2086(2-,6- Month)+ Saline(0-,1- Month)	Serum Bactericidal Assay Using Human Complement (hSBA) Geometric Mean Titers (GMTs)	1M aft Inj4: PMB2948 [B24]; N=354,354,359,228,110	14.7 titer
Group 5: rLP2086(2-,6- Month)+ Saline(0-,1- Month)	Serum Bactericidal Assay Using Human Complement (hSBA) Geometric Mean Titers (GMTs)	1M aft Inj3: PMB2001 [A56]; N=329,339,320,240,102	26.8 titer
Group 5: rLP2086(2-,6- Month)+ Saline(0-,1- Month)	Serum Bactericidal Assay Using Human Complement (hSBA) Geometric Mean Titers (GMTs)	1M aft Inj2: PMB2707 [B44]; N=341,345,349,225,111	4.4 titer
Group 5: rLP2086(2-,6- Month)+ Saline(0-,1- Month)	Serum Bactericidal Assay Using Human Complement (hSBA) Geometric Mean Titers (GMTs)	1M aft Inj4: PMB80 [A22]; N=360,357,369,234,111	39.6 titer
Group 5: rLP2086(2-,6- Month)+ Saline(0-,1- Month)	Serum Bactericidal Assay Using Human Complement (hSBA) Geometric Mean Titers (GMTs)	1M aft Inj3: PMB80 [A22]; N=332,344,340,238,102	16.0 titer

Other Pre-specified

Percentage of Participants Achieving At Least 4-fold Increase in hSBA Titer

Time frame: 1 month after Injection 2, 3, 4

Population: Results were not reported because a decision was made a priori that, although the fold rise outcome measure will still be performed, it will not be performed as a secondary outcome measure. Therefore it was moved from a secondary outcome measure in an earlier protocol version to an exploratory outcome measure in the final protocol.

Source: ClinicalTrials.gov · Data processed: Feb 26, 2026

A Trial To Assess The Safety, Tolerability, And Immunogenicity Of Rlp2086 Vaccine When Administered In Either 2- Or 3-Dose Regimens In Healthy Subjects Aged ≥11 To <19 Years

Conditions

Keywords

Brief summary

Related papers

Interventions

Sponsors

Study design

Eligibility

Inclusion criteria

Exclusion criteria

Design outcomes

Primary

Secondary

Other

Countries

Participant flow

Pre-assignment details

Participants by arm

Withdrawals & dropouts

Baseline characteristics

Adverse events

Outcome results

Percentage of Participants Achieving Serum Bactericidal Assay Using Human Complement (hSBA) Titer Greater Than or Equal to (>=) Lower Limit of Quantitation: Group 1 and 2 Participants

Percentage of Participants Reporting At Least 1 Adverse Event (AE)

Percentage of Participants Achieving hSBA Titer >=LLOQ

Percentage of Participants Achieving hSBA Titer >=LLOQ: Group 3 Participants

Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >= Prespecified Titer Level

Serum Bactericidal Assay Using Human Complement (hSBA) Geometric Mean Titers (GMTs)

Percentage of Participants Achieving At Least 4-fold Increase in hSBA Titer